ДУШЕВНОЕ РАВНОВЕСИЕ


наш форум посвящён теме избавления от депрессии и тревожных расстройств(в т.ч. от ВСД, невроза, панических атак, ОКР, и т.п.). Психологическая взаимопомощь и полезная информация.
Текущее время: 14 июн 2025, 22:02

Часовой пояс: UTC + 3 часа




Начать новую тему Ответить на тему  [ Сообщений: 92 ]  На страницу Пред.  1, 2
Автор Сообщение
СообщениеДобавлено: 09 сен 2017, 11:15 
Не в сети

Зарегистрирован: 29 мар 2015, 13:56
Сообщения: 7049
Пол: Мужской
Bsb17 писал(а):
Недостаток серотонина у человека это личное нарушение баланса , вызванное стрессами или сильный недостаток солнца?
думаю по всякому бывает. Я вот думаю, что моя причина - это сотрясение мозга с потерей сознания в 10 лет. После этого постепенно становилось хуже, мрачно, страшно, не интересно, безсмысленно, видать произошли какие-то органические изменения.
На нормколичество серотонина влияет не только солнце, ещё физнагрузки, воздух, питание и др. Но солнце это конечно сильный фактор, хотя многие так не думают и пренебрегают этим. У меня на работе есть часть отдела где женщины сидят за комп-ми и шторы закрывают и сидят в потёмках и ещё гордятся этим. Думаю это прямой путь к депрессиям. А напарник тоже не любит свет, рассказывает, что днём дома закрывает все шторы и так в потёмках сидит за компом.
Потом у людей вылазит депресняк и они далже понятия не имеют почему это с ними произошло. А есть меднаправление светотерапия, которая предполагает целый день находится при освещении и не важно каком, включить эл.лампы, даже растелить белые простыни по квартире. В Норвегии даже учёные создали такие очки, которые светят в глаза.

__________________________________
С утра: вортиоксетин - 10, окскарбазепин - 150, фенибут - 500;
На ночь: миртазапин - 15 , окскарбазепин - 225, кветиапин - 50, тразодон - 0, левана - 2, габапентин - 0 - 800 или прегабалин - 0 - 300, мелотонин - 20


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 09 сен 2017, 11:39 
Не в сети
Аватара пользователя

Зарегистрирован: 07 июн 2017, 12:10
Сообщения: 3144
Пол: Женский
lyolik
Спасибо за ответ )
lyolik писал(а):
меня на работе есть часть отдела где женщины сидят за комп-ми и шторы закрывают и сидят в потёмках и ещё гордятся этим. Думаю это прямой путь к депрессиям
Я тоже так думаю.
И вот думаю, как быть зимой, ведь встаёшь ещё темно, а в 16ч уже темно. Особенно как сейчас - в связи с обстоятельствами - Мы не в городе, в деревне зимуем . Постоянно темно !
Все время включать больше света... но ведь это не солнце (

lyolik писал(а):
есть меднаправление светотерапия, которая предполагает целый день находится при освещении и не важно каком, включить эл.лампы, даже растелить белые простыни по квартире
Наверное так и придётся )


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 09 сен 2017, 11:54 
Не в сети
Аватара пользователя

Зарегистрирован: 25 май 2017, 16:29
Сообщения: 204
Пол: Мужской
Bsb17 писал(а):
Недостаток серотонина у человека это личное нарушение баланса , вызванное стрессами или сильный недостаток солнца? Или и то и другое ?

Возможно так оно и есть, но мне, например, солнце никакого эффекта не дает. Дома окна на солнечной стороне, а этим летом меня все равно крыло. Мб биполярке пофиг на солнце. А вот стресс качельки расшатывает в депру сильно.

__________________________________
БР1
Ламотриджин (Сейзар) - 150-150-100 мг
Флюанксол (слезаю)
Азафен - 25 мг (утро), 25 мг (день)
Моя тема


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 09 сен 2017, 11:56 
Не в сети

Зарегистрирован: 29 мар 2015, 13:56
Сообщения: 7049
Пол: Мужской
Bsb17 писал(а):
Все время включать больше света... но ведь это не солнце (
Во первых - плевать, можно купить светодиодные лампы, будет совсем не хуже. Во-вторых есть в продаже спецлампы, заменяющие по освещению солнечный свет. Тут ветка есть об этом. Я как-то думал такую лампу купить, но когда появились светодиодные лампы, то передумал. Купил димируемые лампы, то есть можно менять силу освещения. А в продаже есть такие большие цельные лампы с пультом управления, там можно устанавливать свет на любой вкус, и ярче и разного цвета.

__________________________________
С утра: вортиоксетин - 10, окскарбазепин - 150, фенибут - 500;
На ночь: миртазапин - 15 , окскарбазепин - 225, кветиапин - 50, тразодон - 0, левана - 2, габапентин - 0 - 800 или прегабалин - 0 - 300, мелотонин - 20


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 09 сен 2017, 12:41 
Не в сети
Аватара пользователя

Зарегистрирован: 07 июн 2017, 12:10
Сообщения: 3144
Пол: Женский
lyolik писал(а):
Bsb17 писал(а):
Все время включать больше света... но ведь это не солнце (
Во первых - плевать, можно купить светодиодные лампы, будет совсем не хуже. Во-вторых есть в продаже спецлампы, заменяющие по освещению солнечный свет. Тут ветка есть об этом. Я как-то думал такую лампу купить, но когда появились светодиодные лампы, то передумал. Купил димируемые лампы, то есть можно менять силу освещения. А в продаже есть такие большие цельные лампы с пультом управления, там можно устанавливать свет на любой вкус, и ярче и разного цвета.

lyolik
Спасибо большое :thank_you: изучу)


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 09 сен 2017, 12:48 
Не в сети
Аватара пользователя

Зарегистрирован: 03 фев 2017, 16:56
Сообщения: 2706
Пол: Женский
Мне последнее время, как заболела, свет кажется слишком ярким, всегда в темных очках, дома шторы. Но у меня тревога первична.

__________________________________
эсциталопрам - 0 мг


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 09 сен 2017, 14:03 
Не в сети
Аватара пользователя

Зарегистрирован: 28 фев 2017, 21:49
Сообщения: 1680
Пол: Женский
Я крайне болезненно воспринимаю яркий солнечный свет. Уже лет 10. У меня везде жалюзи и очень плотные шторы. По всей квартире диммеры (светорегуляторы) - приглушённый тёплый свет.
"Светотерапия" - для меня непонятная штука по этой причине.

__________________________________
ПТСР, ТДР, аддиктивное расстройство, астения.
Прегабалин
Арипипразол
Десвенлафаксин


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 27 авг 2018, 10:45 
Не в сети
Аватара пользователя

Зарегистрирован: 01 фев 2015, 13:31
Сообщения: 554
Пол: Мужской
Если в обычную настольную лампу вставить светодиодную лампочку 6 ватт на 4000к-белая.
Будет ли толк. Утром после сна облучаться.


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 29 авг 2018, 20:49 
Не в сети
Администратор
Аватара пользователя

Зарегистрирован: 24 дек 2013, 22:02
Сообщения: 8590
Откуда: Санкт-Петербург
Пол: Мужской
Matt писал(а):
Если в обычную настольную лампу вставить светодиодную лампочку 6 ватт на 4000к-белая.
Будет ли толк. Утром после сна облучаться.
Если только направлять её не на стол, а прямо в глаза. Хотябы минут 20-30 с утра и этого может бытьв некоторых случаях достаточно. Ну по крайней мере для поддержки циркадных ритмов и улучшения сна.

__________________________________
Я не врач. Я никого не лечу и лечить не планирую. Ответственности никакой не несу. Всё что я пишу - лишь информация для размышления. Окончательное решение за вами и вашим врачом.


Просьба НЕ писать мне вопросы медицинского характера личным сообщением!

---------------------------------
Правила форума !!!
Отказ от ответственности


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 27 янв 2019, 20:46 
Не в сети
Аватара пользователя

Зарегистрирован: 21 фев 2017, 09:54
Сообщения: 3082
Откуда: Москва
Пол: Мужской
Сезонная депрессия,или Как пережить эту долгую темную зиму. Что такое SAD, и как его избежать

https://vk.com/@-164173721-sad


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 23 июл 2019, 10:57 
Не в сети
Аватара пользователя
Забанен(а)

Зарегистрирован: 17 июл 2019, 12:54
Сообщения: 30
Светотерапия (светолечение или фототерапия) — давно доказавший свою эффективность метод инструментальной (как правило) терапии. Основан он на том, что свет различной длины (в медицине — чаще всего свет от искусственных источников) может влиять на состояние организма человека. Метод широко используется в косметологии, дерматологии, но многим ли известно, что психиатрия — та область, где светотерапия нашла себе широкое применение.

Как метод лечения, светотерапия имеет свои показания и противопоказания. Не стоит воспринимать ее как искусственный загар. Настоящие сеансы светотерапии (то есть, лечения светом), проводятся амбулаторно или в стационаре в строго определенное врачом время, строго определённой волной света, излучаемой специальным аппаратом, и в течение строго определенного количества времени.

Итак, в психиатрии и неврологии данный метод используется при расстройствах сна и аффективных расстройствах.

Светотерапия расстройств суточных (циркадных) ритмов
При отсроченном наступлении сна люди засыпают позже, чем это обычно происходит в норме. В итоге, человек либо вынужден просыпаться не выспавшимся, либо вставать позже. Для лечения этого состояния сеансы светотерапии проводятся в утренние часы, непосредственно после пробуждения. Это делается для того, чтобы человек начинал качественно бодрствовать как можно раньше, и, соответственно, его организм был готов к наступлению сна вечером.
При раннем наступлении фаз сна, когда пациенты склонны засыпать в ранее вечернее время, и, соответственно, пробуждаться еще до наступления утра. В этом случае светотерапия проводится в вечерние часы.
Бывают случаи, когда человек не имеет более или менее постоянного режима засыпания. И здесь сеансы светотерапии, проводимые в строго определенные часы способны наладить правильный режим сна и бодрствования.
Светотерапия аффективных расстройств
Светотерапия аффективных расстройств уже давно зарекомендовала себя как дополнительный метод борьбы с сезонными депрессиями. Компенсация нехватки естественного, природного света в осеннее и зимнее время не только стабилизирует сон, нередко нарушенный при депрессии, но и действует возбуждающе на кору головного мозга, что позволяет человеку выходить из угнетенного состояния. Традиционно считалось, что светотерапия применима лишь для лечения сезонных депрессий, однако, согласно недавним исследованиям, установлено, что она так же дает отличные результаты при лечении всех видов депрессий и биполярных аффективных расстройств.
Так, одно из исследований, проведенное на базе свободного университета Амстердама в 2013 г. показало, что лечении депрессии светом помогает при болезни Альцгеймера, оптимизируя ритмы сна и бодрствования у пациентов. Поскольку у них нередко нарушены циркадные ритмы, дополнительное количество света способствует поддержанию функции, управляющей биологическими часами в головном мозге. После проведенных процедур пациенты реже жаловались на сон, их эмоциональное состояние было более стабильным.

Нужно помнить, что светотерапия никак не может быть панацеей от нарушений сна и депрессии. Если мы говорим о лечении заболевания, то это лишь дополнительный метод, который позволяет добиться результатов терапии более быстрыми темпами, но никак не заменяет других методов лечения полностью. Поскольку в настоящее время лампы для светотерапии могут быть в свободной продаже и доступны всем, кто готов потратить на их покупку солидную сумму денег, все же перед ее применением проконсультируйтесь с лечащим врачом. Метод имеет ряд ограничений и жёстких противопоказаний. Самостоятельное лечение светом может не принести должной пользы.

__________________________________
доктор медицинских наук, профессор В.Л. Минутко


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 27 июн 2021, 10:29 
Не в сети

Зарегистрирован: 16 июн 2021, 13:08
Сообщения: 2
В статье "The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder",
касающейся выбора лечения резистентного биполярного расстройства, в таблице рекомендаций, для разновидности БАР с преобладанием депрессивных фаз, нашёл светотерапию на достаточно высоком месте рекомендаций.
https://drive.google.com/file/d/1bHcFpz ... sp=sharing

Соответственно решил прошерстить гугл на тематические статьи по светотерапии и мета-анализы:
Спойлер: как я понял, большинство исследователей остановились на цветовой температуре 4000К или 10000К, ну и те статьи которые я не нашёл в открытом доступе скачал в pdf их аннотации.

2011 - Pail Gerald - Bright-Light Therapy in the Treatment of Mood Disorders
https://drive.google.com/file/d/1-dc2Vj ... sp=sharing

2017 - Kupeli Nese Yorguner - Efficacy of bright light therapy in bipolar depression
https://drive.google.com/file/d/1-_H-PU ... sp=sharing

2017 - Tian-hang Zhou - Clinical Efficacy, Onset Time and Safety of Bright light Therapy in Acute Bipolar Depression as an Adjunctive Therapy - a Randomized Controlled Trial
https://drive.google.com/file/d/1RkzDJl ... sp=sharing

2018 - Sit Dorothy K. - Adjunctive Bright Light Therapy for Bipolar Depression - A Randomized Double-Blind Placebo-Controlled Trial
https://drive.google.com/file/d/1Pfd0J2 ... sp=sharing

2020 - Hirakawa Hirofumi - A systematic review and meta-analysis of randomized - controlled trials - Adjunctive bright light therapy for treating bipolar depression
https://drive.google.com/file/d/1jsD0Ef ... sp=sharing

2020 - Raymond - Systematic Review and Meta-Analysis of Randomized Controlled Trials - Light Therapy for Patients With Bipolar Depression
https://drive.google.com/file/d/1e3Ii1l ... sp=sharing

2020 - Takeshima Masahiro - A systematic review and meta-analysis - Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder
https://drive.google.com/file/d/1O091Sj ... sp=sharing

2020 - Wang Shengjun - A systematic review and meta-analysis - Bright light therapy in the treatment of patients with bipolar disorder
https://drive.google.com/file/d/1jvoxAx ... sp=sharing

2021 - Sy Atezaz Saeed - A review of 6 studies - Bright light therapy for bipolar depression
https://drive.google.com/file/d/16mUtxP ... sp=sharing


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 08 дек 2021, 13:36 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
https://habr.com/ru/post/517360/

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 11 дек 2023, 22:27 
Не в сети

Зарегистрирован: 23 фев 2023, 18:10
Сообщения: 157
Долгое время борясь с ГБН и фоновым напряжением(фоновая беспричинная тревога), пробуя различную психофарму и естессно без особого результата периодически замечал что при определенном освещении на улице либо в помещении мой мозг расслабляется, как-бы зомбируется что-ли, притормаживается, успокаивается. Всё воздействие происходит через глаза. Сначала расслабляются глаза, потом лоб, макушка, наступает какая-то легкость, могу легко улыбнуться без напряжения. На форуме была тема про светотерапию при лечении депрессии, но там использовался яркий белый свет, в моем случае он наоборот увеличивал напряжение и усиливал ГБН. По моим наблюдениям хороший эффект оказывал именно теплый свет(жёлтый), не тусклый но и не сильно яркий, но ближе к яркому и причем он не должен освещать всё пространство помещения, а светить как бы локально, остальной фон должен быть затемнен.
Поиск в интернете ничего путнего по этому поводу не дал, только лишь ссылки на светотерапию ярким светом при депрессии. Я так понимаю это должна быть лампа, скорее всего лампа накаливания, никак не светодиодная и не флуоресцентная, но с определенной яркостью. Предполагаю, что ежедневное, скажем 20 минутное нахождение под воздействием такого освещения способна снизить фоновое напряжение, кому-то тревоги и прочее. Но найти девайсы с подобным освещением не могу, можь кто сталкивался с ними, либо с подобных эффектом?


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 15:39 
Не в сети
Аватара пользователя

Зарегистрирован: 24 янв 2022, 07:40
Сообщения: 3422
GBNchik писал(а):
Но найти девайсы с подобным освещением не могу, можь кто сталкивался с ними, либо с подобных эффектом?
https://www.ozon.ru/product/hope-light- ... +депрессии

https://www.ozon.ru/product/fototerapiy ... +депрессии
https://www.ozon.ru/product/generic-fot ... +депрессии
Маня писала,что ей помогает,поднимает настроение.
Она часто бывает в этой теме.Можешь задать ей вопросы.
Мир вверх дном. Одним словом, massaraksh


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 15:47 
Не в сети
Аватара пользователя

Зарегистрирован: 24 янв 2022, 07:40
Сообщения: 3422
GBNchik писал(а):
только лишь ссылки на светотерапию ярким светом при депрессии.
:yes: ,других не встречала.


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 16:11 
Не в сети

Зарегистрирован: 22 апр 2022, 12:29
Сообщения: 2392
Strelets xxxx, а ты себе тоже такой купила?

__________________________________
дулоксента 20мг
трилептал, увы, пришлось отменить.
Хронический болевой синдром, СХТБ


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 16:23 
Не в сети
Аватара пользователя

Зарегистрирован: 24 янв 2022, 07:40
Сообщения: 3422
TanyaFem писал(а):
Strelets xxxx, а ты себе тоже такой купила?
Хотела,но нет, не купила.


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 18:06 
Не в сети

Зарегистрирован: 23 фев 2023, 18:10
Сообщения: 157
Strelets xxxx, я такие девайсы видел но там белый яркий свет, при депрессии я так понимаю он растормаживает и подымает как бы таким образом настроение. Жёлтый свет он расслабляет, такой бы девайс с желтым попробовать бы если есть. Видел в салоне автобуса одну такую лампочку в флаконе, она меня прям расслабила конкретно. Уже мысль появилась подойти к водителю и выкупить её :06n:. Если не найду девайс, то придется выкупать автобус :06n:


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 18:25 
Не в сети
Аватара пользователя

Зарегистрирован: 25 ноя 2023, 09:36
Сообщения: 91
Откуда: из воздуха
Пол: Мужской
Свет, цвет, мечтаю сделать ремонт как в детском саду. :blush: Однажды притащил с улицы блестящий пакет, настолько он позитив излучал.

__________________________________
А когда гости затопали ногами и закричали "горько", с потолка упала чугунная люстра и всех убила к чертовой матери.


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 12 дек 2023, 20:53 
Не в сети

Зарегистрирован: 23 фев 2023, 18:10
Сообщения: 157
Одуванчик, для этого есть дача чтоб осуществлять свои мечты, а квартира чтоб как у всех


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 22 дек 2023, 16:36 
Не в сети
Аватара пользователя
Предупреждения: 3

Зарегистрирован: 04 фев 2023, 10:49
Сообщения: 9364
Откуда: регион 24
GBNchik, вот наверно ты такую ищешь?

[center]
[/center]
" onclick="window.open(this.href);return false;">Бессонница (инсомния) - проблема с вечерним засыпанием, ранними пробуждениями, а также другие проблемы со сном.

В конце страницы Эльвирка описывает

__________________________________
"Власть над собой — самая высшая власть."-Сенека Луций Анней


ЦИКЛОТИМИЯ или БАР-3


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 22 дек 2023, 19:48 
Не в сети

Зарегистрирован: 23 фев 2023, 18:10
Сообщения: 157
Waleri_Anka, :90: немного не так её представлял, но интересно, спасибо за ссылку


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 28 июл 2024, 19:50 
Не в сети
Администратор
Аватара пользователя

Зарегистрирован: 24 дек 2013, 22:02
Сообщения: 8590
Откуда: Санкт-Петербург
Пол: Мужской
Изображение

Почти 400 ватт светодиодов холодного света.

__________________________________
Я не врач. Я никого не лечу и лечить не планирую. Ответственности никакой не несу. Всё что я пишу - лишь информация для размышления. Окончательное решение за вами и вашим врачом.


Просьба НЕ писать мне вопросы медицинского характера личным сообщением!

---------------------------------
Правила форума !!!
Отказ от ответственности


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 10 авг 2024, 17:51 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
Dmitriy писал(а):
Изображение

Почти 400 ватт светодиодов холодного света.
Ватты - это хорошо. Но!
Сколько люкс на уровне глаз?
Самый важный показатель - это световой поток на уровне глаз.

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 11 авг 2024, 07:43 
Не в сети
Аватара пользователя
Предупреждения: 3

Зарегистрирован: 04 фев 2023, 10:49
Сообщения: 9364
Откуда: регион 24
На вайлдберриз сейчас много всяких ламп до 10 000 люкс.
Ценник от 1 до 7 000.

https://www.wildberries.ru/catalog/2054 ... etail.aspx

На многие сейчас летняя скидка,осенью-зимой ценник всегда выше.

__________________________________
"Власть над собой — самая высшая власть."-Сенека Луций Анней


ЦИКЛОТИМИЯ или БАР-3


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 11 авг 2024, 10:15 
Не в сети
Администратор
Аватара пользователя

Зарегистрирован: 24 дек 2013, 22:02
Сообщения: 8590
Откуда: Санкт-Петербург
Пол: Мужской
Дивисенко писал(а):
Ватты - это хорошо. Но!
Сколько люкс на уровне глаз?
Самый важный показатель - это световой поток на уровне глаз.
Смартфон показал что-то около 3000 lx для человека, который сидит недалеко и лицом к люстре. Это не 10000, но за счёт того, что можно комфортно "гонять" такую люстру часами, должно быть тоже неплохо. Но у меня сейчас организм уже не реагирует на светотерапию. Раньше реагировал, но то было лет 15 назад.


Waleri_Anka, тут ещё крайне важно, чтобы ей пользоваться было удобно.

__________________________________
Я не врач. Я никого не лечу и лечить не планирую. Ответственности никакой не несу. Всё что я пишу - лишь информация для размышления. Окончательное решение за вами и вашим врачом.


Просьба НЕ писать мне вопросы медицинского характера личным сообщением!

---------------------------------
Правила форума !!!
Отказ от ответственности


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 24 ноя 2024, 14:54 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
Dmitriy писал(а):
Дивисенко писал(а):
Ватты - это хорошо. Но!
Сколько люкс на уровне глаз?
Самый важный показатель - это световой поток на уровне глаз.
Смартфон показал что-то около 3000 lx для человека, который сидит недалеко и лицом к люстре. Это не 10000, но за счёт того, что можно комфортно "гонять" такую люстру часами, должно быть тоже неплохо. Но у меня сейчас организм уже не реагирует на светотерапию. Раньше реагировал, но то было лет 15 назад.


Waleri_Anka, тут ещё крайне важно, чтобы ей пользоваться было удобно.
Спасибо.

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Вернуться к началу
 Профиль  
 
 Заголовок сообщения: Re: Светотерапия (light therapy)
СообщениеДобавлено: 24 ноя 2024, 14:55 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
Сейчас ноябрь и мало солнца в средней полосе.

У кого-то сейчас есть обострение САР (сезонного аффективного расстройства)?

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 07 дек 2024, 16:15 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
Данные из Uptoodate про САР

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 07 дек 2024, 16:26 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
Official reprint from UpToDate®
http://www.uptodate.com © 2024 UpToDate, Inc. and/or its affiliates. All Rights Reserved.



Seasonal affective disorder: Epidemiology, clinical features, assessment, and diagnosis

: David Avery, MD

: Peter P Roy-Byrne, MD

: David Solomon, MD



All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Aug 2024.

This topic last updated: Jun 17, 2024.


INTRODUCTION

The term seasonal affective disorder (SAD) describes episodes of major depression, mania, or hypomania that regularly occur during particular seasons. The most prevalent form of SAD is winter depression, marked by recurrent episodes of unipolar depression that begin in the fall or winter and, if left untreated, generally remit in the following spring or summer. Recognizing the disorder is important because SAD is common and associated with psychosocial impairment [1,2]. In addition, acute treatment is often effective and maintenance treatment can prevent future episodes [3]. Among patients who were recruited for randomized trials studying treatment of winter depression, nearly 60 percent had never been treated for depression [4].

This topic discusses the epidemiology, pathogenesis, clinical features, assessment, diagnosis, and validity of SAD; most of the topic is devoted to recurrent unipolar major depression with winter seasonal pattern (winter depression). Choosing treatment is reviewed separately. (See "Seasonal affective disorder: Treatment".)


DEFINITIONS

Seasonal affective disorder — Seasonal affective disorder (SAD) is defined as recurrent episodes of major depression, mania, or hypomania with seasonal onset and remission [5]. It is not considered a separate mood disorder; rather, SAD is a subtype of the following mood disorders:

● Unipolar major depression (major depressive disorder)

● Bipolar I disorder

● Bipolar II disorder

Thus, patients with SAD have recurrent episodes of unipolar major depression ( table 1), bipolar major depression ( table 2), mania

( table 3), or hypomania ( table 4); the essential feature is that onset and remission of the mood episodes occurs at characteristic times of the year [5].

Subsyndromal SAD consists of recurrent periods of clinically significant mood symptoms that occur with seasonal onset and remission; however, the symptoms do not rise to the level to meet criteria for mood syndromes, such as major depression, and do not substantially impair functioning [1,6].

This topic focuses primarily upon recurrent unipolar major depression with seasonal pattern because it is more common than bipolar disorder with seasonal pattern [7-9]. Among patients with unipolar major depression with seasonal pattern, the winter seasonal pattern is far more common than the summer pattern. (See 'Clinical features' below.)

The clinical features and diagnosis of unipolar major depression and bipolar disorder are discussed separately. (See "Depression in adults: Clinical features and diagnosis" and "Approach to the adult patient with suspected depression" and "Bipolar disorder in adults: Clinical features" and "Bipolar disorder in adults: Assessment and diagnosis".)

Seasonality — SAD is a clinical disorder that is distinguished from seasonality, which represents seasonal changes in mood and behavior [7,10]. Some authorities think that seasonality is distributed along a continuum of severity and that SAD represents one end of the continuum, whereas others conceptualize SAD as a categorical diagnosis [11].
Although seasonality may occur widely in the general population [10,12], it appears that for most individuals in the community, and many patients with mood disorders, the effect of seasonality is modest at most [13-16]. However, seasonal variation in mood and behavior may be greater in patients with depressive syndromes than healthy controls [17].

In addition, placebo response rates in patients with depression may vary in different seasons [18]. A study examined patients with depressive syndromes (n = 432) who were not selected for seasonality and who received a 10-day course of placebo as a “washout” or lead-in to a randomized trial [19]. Response to placebo occurred in fewer patients during the late fall and winter months than the rest of year (15 versus 25 percent).



EPIDEMIOLOGY

General population — In studies from Canada, the United States, and Wales that used interviews rather than self-report questionnaires and used standardized diagnostic criteria for major depression with seasonal pattern, the lifetime prevalence of seasonal affective disorder (SAD) in the general population was approximately 0.5 to 3 percent [20-23]. Studies from the Netherlands and Switzerland using less rigorous methods have found comparable rates [24,25].

Clinical settings — The estimated point prevalence of SAD in outpatients is as follows:

● Primary care patients – 5 to 10 percent [26,27]

● Depressed patients – 15 percent [28,29]

Risk factors — Although risk factors for SAD have been identified, they are likely to have little predictive power for any specific patient.

Most community surveys [29,30] and clinical studies [1] indicate that SAD is more common among women. However, this finding may be due to methodologic problems. As an example, a nationally representative survey using more rigorous methods (interviews and standardized diagnostic criteria) found that the lifetime prevalence of SAD was greater in men than women [20]. The finding that SAD is more common among women in clinical studies may be due to selection bias, and simply reflect the observation that the prevalence of unipolar major depression in general is greater in women. (See "Unipolar depression in adults: Epidemiology", section on 'Sex'.)
The prevalence of SAD in different age groups is not clear, but seems to be greater in adults than either older adults or children and adolescents [1,21]. Onset of SAD is usually between age 20 and 30 years [1].

Individuals residing at higher northern latitudes, which receive less light in winter, may be at increased risk for SAD; however, this is controversial. Some studies have found that the prevalence of SAD was greater in higher latitudes, but case finding relied upon screening instruments [31]. Methodologically more rigorous studies using standardized criteria to diagnose SAD found that latitude was not associated with the prevalence of SAD [1].



PATHOGENESIS

The pathogenesis of seasonal affective disorder (SAD) is not known; the primary hypotheses involve disturbances of circadian rhythms, decreased sensitivity of the retina, genetic factors, and dysregulation of neurotransmitters such as serotonin [32]. These hypotheses are not mutually exclusive.

In one model, the pathogenesis of SAD includes two components: a seasonal factor and a depression factor [7]. Different pathophysiologic mechanisms may underlie each factor. As an example, the seasonal factor may be due to phase delayed circadian rhythms and the depression factor may be due to monoamine (eg, serotonin) dysregulation.

● Circadian rhythms – Circadian (daily) rhythms are physiologic and behavioral changes that oscillate over a 24-hour cycle, primarily in response to light and darkness in the environment. It is hypothesized that the genesis of SAD involves changes in circadian rhythms due to seasonal changes in the length of daylight each day (also referred to as the light-dark cycle) [33-35]. The circadian rhythms affect the timing and duration of sleep [36].

Two hypotheses based upon circadian rhythms have been proposed for the pathogenesis of SAD: the photoperiod hypothesis and the phase shift hypothesis.

• Photoperiod hypothesis – The length of natural daylight each day is called photoperiod, and is shorter in winter and longer in summer. The photoperiod hypothesis of SAD proposes that in vulnerable individuals, the shorter photoperiod in winter induces depression [34,35]. Active secretion of melatonin occurs at night, and the longer duration of melatonin secretion in winter may
trigger depression. A study found that in patients with SAD (winter depression; n = 55), the duration of nocturnal melatonin secretion was longer in winter than summer; among the healthy controls (n = 55), the duration of melatonin secretion was similar in winter and summer [37]. These results suggest that patients with SAD respond to photoperiod in a manner analogous to other mammals, who respond to the shorter photoperiod of winter (and longer duration of melatonin secretion) with a hibernation response. The hypersomnia, increased appetite, and weight gain that characterize winter depression in patients with SAD may be viewed as a type of hibernation response [35]. Other evidence supporting the photoperiod model of SAD comes from studies of light therapy, which suggest that artificial light may extend the photoperiod. Additional information about melatonin is discussed separately. (See "Pharmacotherapy for insomnia in adults", section on 'Melatonin'.)

• Phase shift hypothesis – The phase shift hypothesis proposes that there is an optimal relationship between the timing of circadian rhythms (eg, the body’s minimum temperature and secretion of melatonin) and the timing of sleep, and that misalignment between circadian rhythms and sleep leads to SAD [33,38]. In most patients with SAD, the later dawn in winter and diminished light delays circadian rhythms relative to external clock time and sleep; this shift of circadian rhythms to a later time is called phase delay. These patients respond to artificial morning light that realigns the circadian rhythms with the sleep-wake cycle [39,40]. Among a smaller group of patients with SAD, circadian rhythms shift to an earlier time with respect to sleep (phase advance); these patients may respond to evening light [33,38]. Properly timed doses of melatonin may also correct circadian misalignment and relieve SAD [41].


The suprachiasmatic nucleus in the hypothalamus is often referred to as the master biologic clock or pacemaker [35,42]. This nucleus generates and synchronizes (entrains) internal circadian rhythms with external time cues such as light, and helps control multiple circadian rhythms, such as daily fluctuations in core body temperature, as well as melatonin secretion by the pineal gland.


Bright light can shift the timing of circadian rhythms. Light just before the temperature minimum will typically shift the temperature minimum clockwise to a later time (phase delay). Light soon after the temperature minimum will shift the temperature minimum counterclockwise to an earlier time (phase advance). The timing of the light relative to the temperature minimum will determine how much the circadian rhythms shift.
Darkness generally has the opposite effect of light upon circadian rhythms. Darkness in the morning will cause a phase delay in the rhythms; darkness in the evening will cause a phase advance in the rhythms.

● Noncircadian effects of light – Light may have a direct positive effect on mood. The intrinsically photoactive retinal ganglion cells are especially sensitive to blue light and connect to not only the suprachiasmatic nucleus of the hypothalamus, but also areas of the brain involved in mood regulation, such as the amygdala and the lateral habenular areas [43].

● Retinal subsensitivity – The sensitivity of the retina usually increases during winter as light levels decrease; the retinal subsensitivity hypothesis posits that in SAD, this response is impaired, which in turn may affect circadian entrainment and/or mood [34,44]. Evidence supporting this hypothesis includes the following:

• A study in 65 individuals found that in those with SAD, responses of retinal ganglion cells to light decreased from summer to winter, but not in controls with no history of depression [44]. In winter, retinal responses to light were lower in those with SAD than controls. During summer, retinal responses were comparable in the two groups.

• The prevalence of SAD appears to be greater among individuals with severe visual impairment, compared to individuals with full sight [32].

• Observational studies in patients with SAD suggest that bright light therapy can normalize retinal sensitivity anomalies [45].

● Genetics – There have not been any twin studies of SAD and it is not known if SAD has a heritable component. Nevertheless, studies suggest that genetic factors may be involved in the pathogenesis of SAD:

• A missense variant of the gene for melanopsin (found in photoactive retinal ganglion cells) was associated with an increased risk of SAD, but the variant was seen in only 5 percent of patients with SAD [46].

• In 891 adults, associations were found between clock genes and SAD. The findings supported previously identified associations between CRY2, PER2, and ZBTB20 genes and SAD, and identified links between CLOCK and PER3 genes and SAD [47].

• A family history of depressive and bipolar disorders is present in 25 to 67 percent of patients with SAD, and approximately 15 percent of patients with SAD have a first degree relative with SAD [35]. Although these rates exceed what is found in the general
population, a positive family history may be due to environmental effects, genetic factors, or both.

Twin studies have examined seasonality, which represents seasonal changes in mood and behavior that are less severe than what occur in SAD. These studies suggest that genetic factors account for approximately 30 percent or more of the phenotypic variance [35].


The activity of many genes appears to vary in different seasons. A study of more than 22,000 genes from volunteers (n >1200) found that seasonal variation in gene expression occurred in nearly 25 percent of the genes [48]. Approximately 2300 genes were more active in summer and 2800 were more active in winter. Seasonal variation in gene expression was observed in 9 of the 16 clock genes tested. As an example, the circadian clock gene ARNTL was 50 percent more active in August than February.

● Serotonin – Multiple studies suggest that abnormal functioning of serotonergic neurons in the central nervous system may be involved in SAD:

• Decreased serotonergic activity may occur in SAD because of hyperfunctional activity of the serotonin transporter; this enhanced activity may increase clearance of serotonin from the synaptic cleft and reduce synaptic serotonin concentrations. A study observed that activity of the serotonin transporter was elevated in patients with winter depression compared with healthy controls; in addition, the enhanced activity of the transporter in patients normalized after bright light therapy and during natural summer remission [49].


• Increased levels of the serotonin transporter protein (which are associated with lower synaptic serotonin levels) may also decrease central serotonergic activity in SAD. A study that examined healthy volunteers found that levels of the protein in the brain were greater during the fall and winter, compared with the spring and summer [50].

• A crossover study compared an amino acid beverage containing tryptophan with an amino acid beverage containing no tryptophan in patients with SAD (n = 11) who were in remission during the summer [51]. Tryptophan is the precursor amino acid required for central synthesis of serotonin, and administration of a large amount of amino acids without tryptophan induces hepatic metabolism that transiently depletes tryptophan and reduces brain serotonin. The patients served as their own controls and were randomly assigned to the order in which they received the two beverages; the oral solutions were administered
approximately one week apart. Relapse of depression occurred more often during active tryptophan depletion than sham depletion (8 versus 0 patients [73 versus 0 percent]). Other crossover trials have similarly found that tryptophan depletion increased depressive symptoms in patients with SAD who had remitted after bright light therapy [52,53].

In addition, dysregulation of neurotransmitters other than serotonin may be involved in SAD [7].

Information about neurotransmitters in the general population of patients with unipolar depression is discussed separately. (See "Unipolar depression: Neurobiology", section on 'Neurotransmitters'.)



CLINICAL FEATURES

The clinical features of seasonal affective disorder (SAD) depend upon the specific mood disorder that is present (unipolar major depression, bipolar I disorder, or bipolar II disorder). This section focuses primarily upon patients who have recurrent unipolar major depression with seasonal pattern because it is more common than bipolar disorder with seasonal pattern. Among patients with SAD, it is estimated that bipolar I or II disorder is the underlying condition in no more than 30 percent [7,8]. As an example, a study of consecutive patients treated for SAD (n = 454) at a specialty clinic found that bipolar disorder was present in approximately 10 percent [9].

Seasonal pattern — Among patients with recurrent unipolar major depression with seasonal pattern, two specific patterns have been described [1,5]:

● Fall-winter onset – Fall-winter onset SAD is also known as winter depression. Major depressive episodes begin in the fall to early winter and, if left untreated, generally remit during the following spring and summer. These episodes are usually characterized by increased sleep, increased appetite, carbohydrate craving, and weight gain (symptoms that are also found in major depression with atypical features). Depressive symptoms may recur during the summer if exposure to ambient light is reduced (eg, during persistent cloudy weather).


● Spring-summer onset – Spring-summer onset SAD is also known summer depression; major depressive episodes begin in the spring or summer and remit during the following fall and winter. These episodes are usually marked by typical symptoms of depression, such as insomnia and decreased sleep, and decreased appetite and weight loss.
This topic focuses primarily upon winter depression because it is far more common and widely studied than summer depression [1,5,8].

As an example, a registry study found that the prevalence of winter SAD and summer SAD was 3.0 and 0.1 percent [24].

Symptoms — The symptoms of major depression in patients with SAD and in patients with nonseasonal major depression are the same

( table 1):

● Depressed mood

● Loss of pleasure or interest

● Change in appetite or weight (decreased or increased)

● Sleep disturbance (insomnia or hypersomnia)

● Fatigue or loss of energy

● Neurocognitive dysfunction

● Psychomotor agitation or retardation

● Feelings of worthlessness or guilt

● Suicidal ideation or behavior

Additional information about these symptoms is discussed separately. (See "Depression in adults: Clinical features and diagnosis", section on 'Clinical features'.)

Major depressive episodes in patients with SAD usually include atypical features, such as [4,5,7,42]:

● Increased appetite (especially for carbohydrates)

● Weight gain (eg, 3 to 4 kg [6.6 to 8.8 pounds])

● Hypersomnia (eg, sleeping at least one hour more during winter depression than during summer euthymia)

As an example, a retrospective study compared patients with SAD (recurrent unipolar major depression with seasonal pattern; n = 53) and patients with nonseasonal unipolar major depression (n = 54) who were randomly selected from outpatients attending a specialty mood disorders clinic at a university teaching hospital [54]. Hyperphagia and hypersomnia were more prominent in SAD than nonseasonal depression. However, patients with SAD were less prone to rejection sensitivity than patients with nonseasonal depression,

indicating that SAD overlaps with but is not the same as major depression with atypical features. (See "Depression in adults: Clinical features and diagnosis", section on 'Clinical features'.)

It is worth noting that hypersomnia and insomnia are not mutually exclusive, and that both can occur in SAD. A study of patients with SAD (n = 51) found that both hypersomnia and insomnia were present in 47 percent of patients [55].

Among patients with SAD, the symptom profile of winter depression appears to differ from the symptoms of summer depression. A prospective study of patients with winter SAD (n = 30) and summer SAD (n = 30) found that both groups of patients were characterized by dysphoria, fatigue, and decreased activity and functioning [56]. However, hypersomnia, hyperphagia, carbohydrate craving, and weight gain occurred more frequently in winter depressives than summer depressives. By contrast, decreased appetite and sleep occurred more often in summer depressives.

The frequency of psychotic symptoms in winter depression appears to be rare [1].

Functioning and quality of life — By definition, psychosocial functioning is impaired during episodes of unipolar major depression

( table 1), whether or not a seasonal pattern is present [5]. One study examined patients with SAD (n = 20) and patients with nonseasonal depression who were hospitalized for suicide attempts (n = 20), and found that global functioning and social functioning were each comparable in the two groups [2].

Quality of life, which refers to subjective satisfaction with one’s physical, psychologic, and social functioning, is generally comparable in patients with SAD and patients with nonseasonal unipolar depression [57].

Comorbidity — Patients with SAD often have comorbid psychopathology, including [1,6,7,58-65]:

● Alcohol use disorders

● Attention deficit hyperactivity disorder

● Binge eating disorder

● Bulimia nervosa

● Delayed sleep phase disorder

● Generalized anxiety disorder
● Panic disorder

● Personality disorders

● Premenstrual dysphoric disorder

● Social anxiety disorder

The presence of comorbidity may lead to a chief complaint that is not a key symptom of SAD and thus interfere with recognition of SAD [1]. In addition, the severity of depression appears to be greater in patients with comorbid disorders than patients without comorbidity [65].


High rates of comorbid psychopathology are also found in the general population of patients with major depression. (See "Depression in adults: Clinical features and diagnosis", section on 'Comorbidities'.)

Course of illness — The short-term course of illness in SAD may vary during the fall and winter months. As an example, bright sunny days are associated with improvement of symptoms [66]. In addition, residual symptoms may persist during summer; these symptoms are often amenable to bright-light therapy [67]. It is estimated that over the course of one year, symptoms are present 40 percent of the time [68].


Many patients with winter depression do not suffer a depressive episode the following winter. Prospective studies have found that from one winter to the next, recurrence of depression occurs in only 50 to 70 percent of patients [69].

The seasonal pattern of recurrent unipolar major depression is generally not a long-term phenomenon. In several longitudinal studies of patients who were initially diagnosed with SAD and subsequently evaluated (eg, 5 to 11 years later), recurrent depression with seasonal pattern persisted in less than 50 percent [1]. Approximately 40 percent of patients continued to suffer recurrent major depressive episodes that no longer retained a pattern of winter depression followed by summer remission, and approximately 15 percent recovered with no further episodes of major depression.




ASSESSMENT
Patients with a possible diagnosis of seasonal affective disorder (SAD) are assessed for a recurrent mood disorder in which the onset and remission of the mood episodes occur at characteristic times of the year.

When to suspect the disorder — The presence of recurrent unipolar depression with seasonal pattern (winter depression) is suggested by the following clues [1]:

● Seasonal pattern to the depressive episodes

● Depressive syndrome is usually worse in winter

● Depression is ameliorated by sunshine

● Atypical depressive symptoms

• Hypersomnia

• Hyperphagia (especially carbohydrate craving)

• Weight gain

● Somatic symptoms

In one study of primary care patients, health care utilization (eg, number of outpatient visits, diagnostic tests, and prescriptions) throughout the year was greater in patients with SAD than patients without SAD [70]. During winter, the number of outpatient visits was greater in patients with SAD.

Mood disorder — The evaluation of patients for a diagnosis of SAD begins with an assessment for unipolar major depression or bipolar disorder. (See "Bipolar disorder in adults: Assessment and diagnosis", section on 'Assessment' and "Approach to the adult patient with suspected depression".)

Suicide — All depressed patients should be assessed for suicidal ideation (including plans) and behavior. (See "Suicidal ideation and behavior in adults", section on 'Patient evaluation' and "Approach to the adult patient with suspected depression", section on 'Risk of suicide'.)

Seasonal pattern — Patients with unipolar major depression ( table 1) and a possible diagnosis of fall-winter onset SAD are assessed for recurrent depressive episodes with a seasonal pattern. The interview includes the following questions:
● Do you feel worst (more sad) in the winter?

● Do you eat more in the winter?

● Do you gain weight in the winter?

● Do you sleep more in the winter?

● Do you have less energy in the winter?

● Do you socialize with other people less often in the winter?

● Is the depression ameliorated by sunnier weather?

● Does the depression resolve during travel to a sunnier location or a location with a longer photoperiod (length of natural daylight each day)?

● Does the depression remit during the spring and/or summer?

Hypersomnia may present as difficulty awakening for patients who are disciplined and have to wake up to go to work [71]. Asking about sleep on days when patients are free to sleep in may uncover hypersomnia.

It is useful to ask about exposure to outdoor light. Depressed patients who isolate themselves indoors may create an "eternal winter." Darkness during the summer may perpetuate the depressive syndrome because the patient is not receiving summer light.

The initial assessment asks about mood episodes that may have occurred several years in the past, and it can thus be helpful to gather information from collateral sources, such as family and friends.

Screening — We generally do not use an instrument to screen for SAD. Rather, we verbally ask patients who present with a history of recurrent depressive episodes if the episodes occur with a seasonal pattern. (See 'Seasonal pattern' above.)
For clinicians who choose to screen for SAD, we suggest the self-administered Seasonal Pattern Assessment Questionnaire ( table 5) [72]. The questionnaire includes a six-item scale that assesses seasonal changes in sleep, social activity, mood, weight, appetite, and energy. Each item is rated on a Likert scale ranging from 0 (no change) to 4 (extremely marked change). The scores for each item are summed and the total score ranges from 0 to 24; a score ≥11 is usually used to identify SAD [6,55]. However, this cut-off score is considered overinclusive [1,73]. The psychometric properties of the Seasonal Pattern Assessment Questionnaire range from poor to good, with a sensitivity of 38 to 94 percent, specificity 46 to 79 percent, and positive predictive value 45 to 71 percent [27,74-76]. The questionnaire has good internal consistency, test-retest reliability, and construct validity [76-78], but prospective validity is poor [79].

An alternative to the Seasonal Pattern Assessment Questionnaire is the Seasonal Health Questionnaire, which is longer and has six sections and multiple items within each section [80]. The sensitivity is 59 percent, specificity 97 percent, and positive predictive value 93 percent [27].


Screening questionnaires do not generate a diagnosis of SAD; thus, patients who screen positive require a clinical interview to make the diagnosis. In addition, studies indicate that screening for depression is beneficial only in settings that can provide follow-up to ensure accurate diagnosis and effective treatment. General information about screening for major depression, including the effectiveness of screening, is discussed separately. (See "Screening for depression in adults".)



DIAGNOSIS

Diagnostic criteria — We recommend diagnosing SAD according to the criteria in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) [5]. In DSM-5-TR, SAD is defined as recurrent episodes of major depression, mania, or hypomania with seasonal onset and remission. SAD is not considered a separate mood disorder; rather, SAD is a subtype of the following mood disorders:

● Unipolar major depression (major depressive disorder)

● Bipolar I disorder

● Bipolar II disorder
Patients with SAD thus have recurrent episodes of unipolar major depression ( table 1), bipolar major depression ( table 2), mania

( table 3), or hypomania ( table 4); the essential feature is that onset and remission of the mood episodes occurs at characteristic times of the year [5]. This topic focuses primarily upon patients with recurrent unipolar major depression with seasonal pattern because most of what is known about SAD comes from studies of these patients.

The World Health Organization's International Classification of Diseases, 11th Revision (ICD-11) includes “seasonal depressive disorder” as a subtype of recurrent unipolar depressive disorder; the diagnostic criteria for seasonal depressive disorder resemble those of DSM-5-TR for seasonal affective disorder [81]. The formal ICD-11 diagnostic term for SAD is “recurrent depressive disorder, with seasonal pattern of mood episode onset.”

Unipolar major depression — According to DSM-5-TR, an episode of unipolar major depression manifests with five or more of the following symptoms, present most of the day nearly every day for a minimum of two consecutive weeks ( table 1) [5]. At least one symptom is either depressed mood or loss of interest or pleasure.

● Depressed mood

● Loss of interest or pleasure in most or all activities

● Insomnia or hypersomnia

● Change in appetite or weight

● Psychomotor retardation or agitation

● Low energy

● Poor concentration

● Thoughts of worthlessness or guilt

● Recurrent thoughts about death or suicide

Additional information about the diagnosis of unipolar major depression is discussed separately. (See "Approach to the adult patient with suspected depression".)

With seasonal pattern — The specifier “with seasonal pattern” applies to recurrent major depressive episodes that meet each of the following criteria [5]:
● There is a regular temporal relationship between the onset of major depressive episodes and a particular time of year (eg, fall or winter). However, the specifier is not used for patients with episodes that occur in response to seasonally related psychosocial stressors (eg, unemployment every winter).

● Remission of the episodes (in the absence of treatment) also occurs at a characteristic time of year (eg, spring or summer).

● In each of the last two years, onset and offset of an episode of major depression has occurred at a characteristic time of year, and there have not been any nonseasonal episodes.

● The lifetime course of illness is such that seasonal episodes of major depression substantially outnumber the nonseasonal episodes (eg, by a ratio of two to one).

Bipolar disorder — The diagnosis of bipolar disorder, including bipolar disorder with a seasonal pattern, is discussed separately. (See "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'.)

Differential diagnosis — The disorder at the top of the differential diagnosis for SAD is nonseasonal major depression, particularly nonseasonal major depression with atypical features. Both SAD and nonseasonal major depression consist of major depressive episodes (see 'Unipolar major depression' above). However, SAD is distinguished by onset and remission of recurrent episodes at characteristic times of the year (eg, winter) [5]. In nonseasonal major depression, there is no temporal relationship between recurrence/remission of major depressive episodes and a particular time of year. Although SAD and nonseasonal major depression with atypical features can share certain symptoms (such as hyperphagia, weight gain, and hypersomnia), the two disorders are differentiated by whether the depressive episodes occur with a seasonal pattern. (See 'With seasonal pattern' above.)

Other disorders that constitute the differential diagnosis for SAD are similar to disorders found in the differential diagnosis for unipolar major depression and bipolar disorder [7]. (See "Bipolar disorder in adults: Assessment and diagnosis", section on 'Differential diagnosis' and "Approach to the adult patient with suspected depression", section on 'Further assessment and differential diagnosis'.)




SYNDROMAL VALIDITY
DSM-5-TR recognizes SAD as a subtype of recurrent mood disorders [5], and ICD-11 recognizes seasonal depressive disorder as a subtype of recurrent depressive disorders [81]. SAD is thought to be a valid clinical syndrome, based upon its face validity (extent to which experts think the concept is distinct), descriptive validity (extent to which the defining characteristics of the illness are unique to the disease), predictive validity (extent to which one can predict the course of illness and response to treatment), and construct validity (extent to which the defining characteristics, boundaries, and pathophysiology of a disorder are known) [10].

Evidence supporting the syndromal validity of SAD includes the following:

● The clinical manifestation of winter depression is distinct and predictable, such that patients regularly present with depression in the fall or winter and remit in the spring or summer [11]. As an example, prospective studies that recruited euthymic patients with SAD during summer months have found that patients became depressed in the fall and winter.

● Winter depressive episodes characteristically and consistently manifest some atypical features [11]. (See 'Symptoms' above.)

● SAD has been observed in both the southern and northern hemispheres [82].

● Neurobiologic studies suggest that patients with SAD differ from patients with nonseasonal major depression and healthy controls. As an example, studies of patients with SAD have observed seasonal changes in melatonin secretion and found that processing of visual light is impaired [11].

Nevertheless, some clinicians doubt that SAD is a valid syndrome [8,83]. Arguments put forth that SAD is not a distinct entity include the following:

● SAD symptoms (eg, hyperphagia and hypersomnia) overlap with symptoms of major depression with atypical features [5,10]. However, this argument is undermined by lack of overlap with regard to other atypical symptoms (see 'Symptoms' above). In addition, an observational study found that bright light therapy was more effective for SAD than atypical depression [84].

● The boundary between SAD and the seasonal variations in mood and behavior found in the general population (called seasonality) is not clearly delineated [10]. When the Seasonal Pattern Assessment Questionnaire is administered to the general population, the histogram of the frequencies of each score does not have a bimodal distribution; instead, there is a continuum of the frequencies
ranging from no seasonality to mild seasonality to SAD [12]. However, this lack of distinct boundaries exists for other psychiatric syndromes.

● SAD responds to a variety of antidepressants that are also efficacious for nonseasonal major depression [85-88]. However, this argument is undermined by the fact that antidepressants are efficacious for several disorders other than nonseasonal major depression, including anxiety disorders, bulimia nervosa, and fibromyalgia.

● Response to light therapy is not specific to SAD. Multiple randomized trials, especially high quality trials, have demonstrated that bright light therapy is efficacious for nonseasonal depression [89-94]. However, three observational studies each found that the benefit of bright light therapy was greater in patients with SAD than patients with nonseasonal depression [90].

● SAD is uncommon in at least one northern country, Iceland [95]. However, this finding may be explained by genetic factors; the prevalence of SAD is lower in Canadians of Icelandic descent compared with non-Icelandic Canadians [96].

● One study examined depression in a random sample of adults (n >34,000) who lived in different geographical areas in the United States and were assessed with a single, cross-sectional telephone survey at various times of the year [97,98]. The study found no relationship between the level of depression and the season of the year or latitude, and questioned the validity of seasonal affective disorder. However, the study did not ask subjects about a seasonal pattern, had no longitudinal assessment in an illness characterized by its longitudinal course, and had other methodologic problems [99].



INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

● Basics topics (see "Patient education: Seasonal affective disorder (The Basics)")

Additional information for patients about seasonal affective disorder is provided by the Society for Light Therapy and Biological Rhythms and Center for Environmental Therapeutics.



SUMMARY

● Definition – Seasonal affective disorder (SAD) is defined as recurrent episodes of major depression, mania, or hypomania with seasonal onset and remission. It is not considered a separate mood disorder; rather, SAD is a subtype of the following mood disorders: unipolar major depressive disorder, bipolar I disorder, and bipolar II disorder. (See 'Seasonal affective disorder' above.)

● Prevalence – The estimated lifetime prevalence of SAD in the general population is approximately 0.5 to 3 percent. The point prevalence in primary care outpatients is approximately 5 to 10 percent, and in depressed outpatients is 15 percent. (See 'Epidemiology' above.)

● Pathogenesis– The pathogenesis of SAD is not known; the primary hypotheses involve disturbances of circadian rhythms, decreased sensitivity of the retina, genetic factors, and dysregulation of neurotransmitters. (See 'Pathogenesis' above.)

● Clinical features

• Seasonal pattern – Two specific patterns of recurrent unipolar major depression with seasonal pattern have been described. Fall-winter onset SAD (winter depression) begins in the fall to early winter and, if left untreated, generally remits during the following spring and summer. Spring-summer onset SAD (summer depression) begins in the spring or summer and remits during the following fall and winter. Winter depression is far more common than summer depression. (See 'Seasonal pattern' above.)
• Symptoms – The symptoms of major depression in patients with fall-winter onset SAD and in patients with nonseasonal major depression are the same, and include depressed mood, loss of pleasure or interest, change in appetite or weight, sleep disturbance, loss of energy, neurocognitive dysfunction, psychomotor agitation or retardation, feelings of worthlessness or guilt, and suicidal ideation or behavior ( table 1). However, major depressive episodes in patients with SAD usually include atypical features, such as hypersomnia, hyperphagia (especially carbohydrates), and weight gain. (See 'Symptoms' above.)

• Course of illness – The seasonal pattern of recurrent unipolar major depression is generally not a long-term phenomenon. Among patients who are initially diagnosed with fall-winter onset SAD and subsequently evaluated (eg, 5 to 11 years later), recurrent depression with seasonal pattern persists in less than 50 percent. (See 'Course of illness' above.)

● Assessment – Patients with unipolar major depression and a possible diagnosis of fall-winter onset SAD are assessed for recurrent depressive episodes with a seasonal pattern. The interview includes the following questions:

• Do you feel worst (more sad) in the winter?

• Do you eat more in the winter?

• Do you sleep more in the winter?

• Do you have less energy in the winter?

• Do you socialize with other people less often in the winter?

• Is the depression ameliorated by sunnier weather?

• Does the depression remit during the spring and/or summer?

(See 'Seasonal pattern' above.)

● Diagnosis – The diagnosis of SAD requires that patients meet criteria for a recurrent mood disorder with seasonal pattern. In patients who have recurrent unipolar major depression ( table 1) with a fall-winter onset seasonal pattern, each of the following
is present:

• There is a regular temporal relationship between the onset of major depressive episodes and a particular time of year (fall or winter). However, episodes that occur in response to seasonally related psychosocial stressors (eg, unemployment every winter) do not count toward meeting this criterion.

• Remission of the episodes also occurs at a characteristic time of year (spring or summer).

• In each of the last two years, onset and offset of a major depressive episode has occurred at a characteristic time of year, and there have not been any nonseasonal episodes.

• The lifetime course of illness is such that seasonal depressive episodes substantially outnumber the nonseasonal episodes (eg, by a ratio of two to one).

(See 'Unipolar major depression' above.)




ACKNOWLEDGMENT

The UpToDate editorial staff acknowledges Sy Atezaz Saeed, MD and Timothy J Bruce, PhD who contributed to an earlier version of this topic review.

Use of UpToDate is subject to the Terms of Use.



DSM-5-TR diagnostic criteria for a major depressive episode


A. Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.

NOTE: Do not include symptoms that are clearly attributable to another medical condition.


1) Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad, empty, hopeless) or observations made by others (eg, appears tearful). (NOTE: In children and adolescents, can be irritable mood.)

2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).

3) Significant weight loss when not dieting or weight gain (eg, a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (NOTE: In children, consider failure to make expected weight gain.)


4) Insomnia or hypersomnia nearly every day.


5) Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).


6) Fatigue or loss of energy nearly every day.


7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).

8) Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by their subjective account or as observed by others).


9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.


B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.


C. The episode is not attributable to the direct physiological effects of a substance or to another medical condition.


NOTE: Criteria A through C represent a major depressive episode.


NOTE: Responses to a significant loss (eg, bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a
depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgement based on the individual's history and the cultural norms for the expression of distress in the context of loss.


D. The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.


E. There has never been a manic or hypomanic episode.


NOTE: This exclusion does not apply if all of the manic-like or hypomanic-like episodes are substance-induced or are attributable to the physiological effects of another medical condition.


Specify:


With anxious distress


With mixed features


With melancholic features


With atypical features


With psychotic features


With catatonia


With peripartum onset


With seasonal pattern

Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note:

These diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.



Graphic 89994 Version 16.0
DSM-5-TR diagnostic criteria for bipolar major depression



A. Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.

NOTE: Do not include symptoms that are clearly attributable to another medical condition.

1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad, empty, hopeless) or observations made by others (eg, appears tearful). (NOTE: In children and adolescents can be irritable mood.)
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).
3. Significant weight loss when not dieting or weight gain (eg, a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (NOTE: In children, consider failure to make expected weight gain.)

4. Insomnia or hypersomnia nearly every day.

5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).

6. Fatigue or loss of energy nearly every day.

7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by their subjective account or as observed by others).

9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.


B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.


C. The episode is not attributable to the direct physiological effects of a substance or to another medical condition.


NOTE: Criteria A through C represent a major depressive episode.


NOTE: Responses to a significant loss (eg, bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgement based on the individual's history and the cultural norms for the expression of distress in the context of loss.
D. The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.


Specify:

With anxious distress

With mixed features

With rapid cycling

With melancholic features

With atypical features

With psychotic features

With catatonia

With peripartum onset

With seasonal pattern


Adapted from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note: The original diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.


Graphic 91398 Version 10.0
DSM-5-TR diagnostic criteria for manic episode



A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least one week and present most of the day, nearly every day (or any duration if hospitalization is necessary).

B. During the period of mood disturbance and increased energy or activity, three (or more) of the following symptoms (four if the mood is only irritable) are present to a significant degree and represent a noticeable change from usual behavior:
1. Inflated self-esteem or grandiosity.

2. Decreased need for sleep (eg, feels rested after only three hours of sleep).

3. More talkative than usual or pressure to keep talking.

4. Flight of ideas or subjective experience that thoughts are racing.

5. Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli), as reported or observed.

6. Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation (ie, purposeless non-goal-directed activity).
7. Excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments).

C. The mood disturbance is sufficiently severe to cause marked impairment in social or occupational functioning or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features.

D. The episode is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication, other treatment) or to another medical condition.

NOTE: A full manic episode that emerges during antidepressant treatment (eg, medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a manic episode and, therefore, a bipolar I diagnosis.


NOTE: Criteria A through D constitute a manic episode. At least one lifetime manic episode is required for the diagnosis of bipolar I disorder.



Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note:

These diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.


Graphic 91106 Version 8.0
DSM-5-TR diagnostic criteria for hypomanic episode



A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least four consecutive days and present most of the day, nearly every day.

B. During the period of mood disturbance and increased energy and activity, three (or more) of the following symptoms (four if the mood is only irritable) have persisted, represent a noticeable change from usual behavior, and have been present to a significant degree:
1. Inflated self-esteem or grandiosity.

2. Decreased need for sleep (eg, feels rested after only three hours of sleep).

3. More talkative than usual or pressure to keep talking.

4. Flight of ideas or subjective experience that thoughts are racing.

5. Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli), as reported or observed.

6. Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation.

7. Excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments).


C. The episode is associated with an unequivocal change in functioning that is uncharacteristic of the individual when not symptomatic.


D. The disturbance in mood and the change in functioning are observable by others.


E. The episode is not severe enough to cause marked impairment in social or occupational functioning or to necessitate hospitalization. If there are psychotic features, the episode is, by definition, manic.

F. The episode is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication, or other treatment).

NOTE: A full hypomanic episode that emerges during antidepressant treatment (eg, medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a hypomanic episode diagnosis. However, caution is indicated so that one or two symptoms (particularly increased irritability, edginess, or agitation following antidepressant use) are not taken as sufficient for a diagnosis of a hypomanic episode, nor necessarily indicative of a bipolar diathesis.


NOTE: Criteria A through F constitute a hypomanic episode. Hypomanic episodes are common in bipolar I disorder but are not required for the diagnosis of bipolar I disorder.
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note:

These diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.



Graphic 91107 Version 7.0
Modified seasonal pattern assessment questionnaire


Name: Age:
Date of birth: Sex:
(dd/mm/yyyy) Male

Female
Date form completed:
(dd/mm/yyyy)



1. To what degree do each of the following change with the seasons? (Mark one square only per question.)


0 1 2 3 4
No change Slight Moderate Marked Extremely
change change change marked
change


A. Sleep length


B. Social activity (including family, friends, and coworkers)


C. Mood (overall feeling of well being)


D. Weight


E. Appetite


F. Energy level


Total score:__________

2. If you experience changes with the seasons, do you feel that these are a problem for you?


No
Yes


If yes, is the problem... Mild Moderate Marked Severe Disabling


3. Do you typically feel worst in Winter?


No

Yes



A positive screen requires each of the following:

1. Global seasonality score ≥11

2. Seasonal changes are a problem to at least a moderate degree in mood and behavior (eg, sleep, social activity, and weight)

3. Patient feels worst in winter

Patients who screen positive for seasonal affective disorder should be interviewed to establish the diagnosis.



Modified from: Rosenthal NE, Bradt GH, Wehr TA. Seasonal pattern assessment questionnaire. Bethesda, MD, National Institute of Mental Health, 1984.

Graphic 102614 Version 2.0
Contributor Disclosures

David Avery, MD No relevant financial relationship(s) with ineligible companies to disclose. Peter P Roy-Byrne, MD No relevant financial relationship(s) with ineligible companies to disclose. David Solomon, MD No relevant financial relationship(s) with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Последний раз редактировалось Дивисенко 07 дек 2024, 16:35, всего редактировалось 1 раз.

Вернуться к началу
 Профиль  
 
СообщениеДобавлено: 07 дек 2024, 16:34 
Не в сети
Врач
Аватара пользователя

Зарегистрирован: 22 окт 2015, 12:52
Сообщения: 1627
Откуда: Москва
Пол: Мужской
Seasonal affective disorder: Treatment
: David Avery, MD

Peter P Roy-Byrne, MD

David Solomon, MD


All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Aug 2024.

INTRODUCTION

The term seasonal affective disorder (SAD) describes episodes of major depression, mania, or hypomania that regularly occur during particular seasons. The most prevalent form of SAD is winter depression, marked by recurrent episodes of unipolar depression that begin in the fall or winter and if left untreated, generally remit in the following spring or summer. Recognizing the disorder is important because SAD is common and associated with psychosocial impairment [1,2]. In addition, acute treatment is often effective and maintenance treatment can prevent future episodes [3]. Among patients who were recruited for randomized trials studying treatment of winter depression, nearly 60 percent had never been treated for depression [4].

This topic discusses the treatment of SAD; most of the topic is devoted to recurrent unipolar major depression with winter seasonal pattern (winter depression). The epidemiology, neurobiology, clinical features, assessment, diagnosis, and validity of SAD are discussed separately. (See "Seasonal affective disorder: Epidemiology, clinical features, assessment, and diagnosis".)
DEFINITIONS

Seasonal affective disorder — Seasonal affective disorder (SAD) is defined as recurrent episodes of major depression, mania, or hypomania with seasonal onset and remission. It is not considered a separate mood disorder; rather, SAD is a subtype of the following mood disorders [5]:

● Unipolar major depressive disorder (major depressive disorder)

● Bipolar I disorder

● Bipolar II disorder

Thus, patients with SAD have recurrent episodes of unipolar major depression ( table 1), bipolar major depression ( table 2), mania

( table 3), or hypomania ( table 4); the essential feature is that onset and remission of the mood episodes occurs at characteristic times of the year [5].

Subsyndromal SAD consists of recurrent periods of clinically significant mood symptoms (eg, minor depression) that occur with seasonal onset and remission; however, the symptoms do not rise to the level to meet criteria for mood syndromes such as major depression and do not substantially impair functioning [1,6].

This topic focuses primarily upon recurrent unipolar major depression with seasonal pattern because it is more common than bipolar disorder with seasonal pattern [7,8]. (See "Seasonal affective disorder: Epidemiology, clinical features, assessment, and diagnosis", section on 'Clinical features'.)

The clinical features and diagnosis of unipolar major depression and bipolar disorder are discussed separately. (See "Depression in adults: Clinical features and diagnosis" and "Approach to the adult patient with suspected depression" and "Bipolar disorder in adults: Clinical features" and "Bipolar disorder in adults: Assessment and diagnosis".)

Seasonal pattern — Among patients with SAD who have recurrent unipolar major depression with seasonal pattern, two specific patterns have been described [1,5]:
● Fall-winter onset – Fall-winter onset SAD is also known as winter depression. Major depressive episodes begin in the fall to early winter and, if left untreated, generally remit during the following spring or summer. These episodes are generally characterized by increased sleep, increased appetite, carbohydrate craving, and weight gain, symptoms that are also found in major depression with atypical features. (See "Depression in adults: Clinical features and diagnosis".)

● Spring-summer onset – Spring-summer onset SAD is also known as summer depression; major depressive episodes begin in the spring or summer and, if left untreated, remit during the following fall or winter. These episodes are usually marked by typical symptoms of depression, such as insomnia and decreased sleep, as well as decreased appetite and weight loss.

This topic focuses primarily upon winter depression because it is far more common and widely studied than summer depression. (See "Seasonal affective disorder: Epidemiology, clinical features, assessment, and diagnosis", section on 'Seasonal pattern'.)


GENERAL PRINCIPLES

Type of seasonal affective disorder — The treatment of seasonal affective disorder (SAD) depends upon the specific mood disorder that is present, and the type of seasonal pattern (see 'Seasonal pattern' above):

● Unipolar major depression ( table 1)

• Fall-winter onset (see 'Winter depression' below)

• Spring-summer onset (see 'Summer depression' below)

● Bipolar disorder (see 'Bipolar disorder with seasonal pattern' below)

This topic focuses primarily upon winter depression, which is marked by regularly recurring unipolar depressive episodes that begin in the fall or winter and, if left untreated, generally remit during the following spring or summer. Winter depression is the most prevalent form of SAD.


Severity of winter depression — Treatment of winter depression is influenced by severity of illness:
● Severe illness – Severe major depression is characterized by seven to nine depressive symptoms ( table 1) that are present nearly every day and are seriously distressing, and is also marked by obvious impairment of daily functioning [5]. Patients with severe major depression who are assessed with the self-administered Patient Health Questionnaire – Nine Item (PHQ-9) ( table 5) typically score 20 or more points, and often report suicidal ideation and behavior. In addition, severely ill patients are more likely to experience complications, such as psychotic features or catatonic features, and are often referred to psychiatrists for management.

● Mild to moderate illness – Patients with major depression who are mildly to moderately ill often have only five or six depressive symptoms ( table 1) (at least five are necessary to make the diagnosis) [5]. Symptoms are distressing but manageable, and functional impairment is not necessarily obvious to others. Patients with mild to moderate major depression who are assessed with the self-administered PHQ-9 ( table 5) typically score less than 20 points, and often deny suicidal behavior. In addition, patients are unlikely to experience complications, such as psychotic features or catatonic features, and are typically managed by primary care clinicians or mental health clinicians other than psychiatrists.

Assessing prior response to pharmacotherapy — Caution is warranted in assessing prior responses to antidepressant medications in patients with winter depression; a previous “response” in the spring or summer may have been a placebo response rather than a true medication response. In placebo-controlled antidepressant trials, patients with major depression (not selected for the presence or absence of seasonal pattern) are less likely to have a placebo response from November through February compared with other times of the year [9]. As an example, a study examined patients with depressive syndromes (n = 432) who were not selected for seasonality and who received a 10-day course of placebo as a “washout” or lead-in to a randomized trial [10]. Response to placebo occurred in fewer patients during the late fall and winter months than the rest of year (15 versus 25 percent).

Monitoring — For patients with SAD who have recurrent unipolar major depression with seasonal pattern, we suggest monitoring response to treatment in manner similar to that for patients with nonseasonal depression. (See "Depression in adults: General principles and prognosis", section on 'Adherence to treatment'.)

Duration of an adequate trial — Patients with winter depression who receive bright light therapy usually respond within one to four weeks of starting treatment [11-13]. However, a longer course of therapy may be necessary before deciding that the treatment has failed. (See 'Administration' below.)
The duration of an adequate trial of an antidepressant drug for unipolar major depression is discussed separately. (See "Major depressive disorder in adults: Approach to initial management" and "Major depressive disorder in adults: Initial treatment with antidepressants", section on 'Ensure duration of adequate trial'.)

Time-limited psychotherapies, such as cognitive-behavioral therapy or interpersonal psychotherapy, are generally administered until patients have received the entire course of therapy. As an example, cognitive-behavioral therapy adapted for SAD consists of two sessions per week for six weeks [14].

Managing treatment resistance — Patients with winter depression often do not respond to first line treatment. General steps to take for treatment resistance include [12]:

● Verifying the diagnosis

● Verifying adherence with treatment at an adequate dose, for an adequate duration

● Looking for factors that can lead to nonresponse:

• Psychiatric comorbidity, such as undisclosed or unrecognized anxiety disorders, substance use disorders, or personality disorders.

• General medical comorbidity.

• Medication-induced depression (eg, depression secondary to glucocorticoids). (See "Unipolar depression: Pathogenesis", section on 'Medications'.)

• Rapid metabolism of drugs due to genetic polymorphisms of hepatic enzymes – Measuring drug serum concentrations can help determine if larger drug doses are required.

• Cataracts that interfere with light therapy.

• Psychosocial problems (eg, occupational or interpersonal difficulties).
For patients with winter depression who do not respond to first line treatment, despite verifying the diagnosis and adherence and ruling out factors that can cause nonresponse, we recommend the next step treatments that are discussed below. (See 'Approach to acute treatment' below.)

Referral — Winter depression can be managed by primary care clinicians, provided they are comfortable prescribing artificial light. However, treatment resistant patients and patients with severe episodes (eg, suicidal ideation and behavior) are typically referred to mental health clinicians, such as psychiatrists [15].


WINTER DEPRESSION

Winter depression is characterized by recurrent episodes of unipolar major depression that begin in the fall to early winter, and if left untreated, generally remit during the following spring or summer. Winter depression is the most prevalent type of seasonal affective disorder (SAD). (See 'Definitions' above.)

Approach to acute treatment — We suggest that acute treatment of winter depression proceed according to the sequence described in the subsections below. Patients initially receive first line therapy and progress through each step until they respond. The duration of an adequate treatment trial is discussed elsewhere in this topic. (See 'Duration of an adequate trial' above.)

Following response, treatment continues for at least two weeks beyond the usual spring or summer offset of winter depression. (See 'Maintenance treatment' below.)

The primary treatments suggested in the subsections below, either as monotherapy or combination therapy, include:

● Antidepressants

● Light therapy

● Psychotherapy

In addition, we encourage patients to incorporate all the following adjunctive interventions throughout their entire course of acute (and maintenance) treatment:
● Sleep hygiene ( table 6)

● Daily walks outside, even on cloudy days

● Aerobic exercise

● Enhanced indoor lighting with regular lamps and fixtures

● Dawn simulation (see 'Dawn simulation' below)

Sleep hygiene ( table 6), including a regular sleep-wake cycle, is important for treating SAD because hypersomnia and insomnia are common in SAD. As part of sleep hygiene, creating a regular light-dark cycle may be important. Minimizing light exposure, especially blue light from computer monitors and televisions, in the late evening (eg, during the two hours prior to the desired time of sleep onset) may facilitate sleep onset.

Evidence for the efficacy of acute treatments for winter depression is discussed elsewhere in this topic. (See 'Efficacy of acute treatment' below.)

First line — For patients with winter depression, we suggest an antidepressant drug plus artificial light (bright light therapy, dawn simulation, or both) as first line treatment. However, antidepressants alone are a reasonable alternative. The specific choice depends upon factors such as prior treatment history, severity of illness (see 'Severity of winter depression' above), safety, tolerability, cost, and patient preference. As an example, more severely ill patients may benefit from pharmacotherapy plus both bright light therapy and dawn simulation, rather than just one form of light therapy. Some patients prefer antidepressant monotherapy because of relative contraindications to bright light therapy (eg, retinal disease or use of photosensitizing medications) or because bright light therapy is inconvenient and tedious [16]. Dawn simulation is appealing because it is administered at the end of the night, while patients are still asleep; however, the device may wake a sleeping partner. First line treatment with pharmacotherapy plus light therapy or pharmacotherapy alone is consistent with multiple treatment guidelines (eg, American Psychiatric Association and World Federation of Societies for Biological Psychiatry) [12,17-19].


The initial drug of choice for winter SAD is typically a selective serotonin reuptake inhibitor (SSRI) [20], consistent with initial treatment in the general population of patients with unipolar major depression. However, other types of antidepressants can be used instead of SSRIs [8]. As an example, bupropion is a good choice for patients who want to stop smoking tobacco or want to avoid SSRI side effects, such as weight gain or sexual dysfunction. In addition, bupropion has demonstrated efficacy in preventing recurrences of winter depression (see
'Antidepressants' below). Additional information about the general treatment of unipolar major depression, including the choice of drug, doses, and side effects, is discussed separately. (See "Major depressive disorder in adults: Approach to initial management", section on 'Antidepressant medications' and "Major depressive disorder in adults: Approach to initial management".)

For patients with mild to moderate winter depression, light therapy (bright light therapy and/or dawn simulation) alone is also a reasonable alternative as first line therapy, and is consistent with multiple treatment guidelines (eg, American Psychiatric Association and Canadian Network for Mood and Anxiety Treatments) [12,13,17,18,21]. Patients may prefer light therapy alone because it avoids medication safety risks and side effects. However, light therapy alone is generally regarded as inadequate for severe episodes of winter depression. The administration, safety, and side effects of bright light therapy are discussed elsewhere in this topic (see 'Bright light therapy' below), as is the administration of dawn simulation (see 'Dawn simulation' below).

Second line — Winter depression often does not respond to first line treatment with an antidepressant drug plus light therapy. For these patients, the next step is to verify the diagnosis and adherence, and to address factors that can cause nonresponse (see 'Managing treatment resistance' above). If this step is completed and the patient remains unresponsive, we suggest switching antidepressants and continuing light therapy. If patients do not respond to one drug switch, the antidepressant is switched at least one or two more times. Switching antidepressants for managing treatment resistant depression is consistent with multiple practice guidelines (eg, the American Psychiatric Association, Canadian Network for Mood and Anxiety Treatments, and United Kingdom National Institute of Health and Clinical Excellence guidelines) [8,22-26]. Choosing an alternative antidepressant and the process of switching antidepressants are discussed separately. (See "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Next step treatment' and "Switching antidepressant medications in adults".)


For patients with winter depression who partially respond to first line treatment with antidepressants alone, we suggest continuing the drug and adding artificial light (bright light therapy, dawn simulation, or both), as second line treatment. For patients who respond minimally or not all to first line treatment with antidepressants alone, we suggest switching the drug and adding light therapy.

For patients with winter depression who do not respond satisfactorily to first line treatment with light therapy alone, we suggest continuing light therapy and adding an antidepressant drug as second line treatment.
Third line — For patients with winter depression who do not respond satisfactorily to first and second line therapies, we suggest adding psychotherapy as third line treatment. Adjunctive psychotherapy may increase adherence and reduce distress. We typically use cognitive-behavioral therapy (CBT); however, other psychotherapies (eg, interpersonal psychotherapy) are reasonable alternatives. The availability of psychotherapy is often limited, especially CBT that is specifically adapted for SAD.

Other options — For patients with severe winter depression (see 'Severity of winter depression' above) who do not respond to first, second, and third line therapies, we suggest electroconvulsive therapy (ECT). One review noted that among patients with SAD, ECT was required for approximately 2 percent [1].

Numerous studies have demonstrated the effectiveness of ECT for treating severe major depression [27]. Although no high-quality studies have evaluated ECT in patients with winter depression, the indications for using ECT can be extrapolated from nonseasonal depressive episodes and include nonresponse to other established treatments, high suicide risk, psychotic features, and previous positive response to ECT [28]. (See "Unipolar major depression in adults: Indications for and efficacy of acute electroconvulsive therapy (ECT)".)


Negative air ionization [29-33], exogenous melatonin [34,35], or the melatonergic antidepressant agomelatine [36] may perhaps help patients with SAD, but these treatments are generally not used. Although some studies suggest that blue light therapy can be helpful [37-39], it remains an investigational approach because of concerns about retinal damage [40-42].

Efficacy of acute treatment — A limited number of head-to-head randomized trials have compared the efficacy of different acute treatments in patients with winter depression.

Antidepressants plus light therapy — Prescribing an antidepressant plus bright light therapy for SAD (winter depression) is common [29,43] and is based upon indirect evidence from randomized trials in patients with nonseasonal major depression; these trials have shown that antidepressants plus bright light therapy are superior to monotherapy with an antidepressant or bright light therapy. (See "Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Bright light therapy'.)

Antidepressants — Indirect evidence that antidepressant drugs are efficacious for unipolar major depression with seasonal pattern includes the many randomized trials conducted in the general population of patients with unipolar major depression. As an example, a meta-analysis of patient level data from 37 randomized trials (n >8400 patients with major depression) compared either fluoxetine (modal dose 20 mg per day) or venlafaxine (modal dose range 75 to 150 mg per day) with placebo for six weeks; remission occurred in more patients who received active drug than placebo (43 versus 29 percent) [44]. Additional information about the efficacy of antidepressants for the general treatment of unipolar major depression is discussed separately. (See "Major depressive disorder in adults: Approach to initial management", section on 'Efficacy of antidepressants'.)

Randomized trials conducted in patients with SAD (winter depression) also indicate that antidepressant drugs can be beneficial, at doses similar to those used for nonseasonal depression [45]. Clinicians can expect that response will occur in approximately 60 percent of patients:


● An eight-week trial compared sertraline (50 to 200 mg/day) with placebo in 102 patients with SAD and found that response (much or very much improved) was greater in patients who received sertraline than placebo (62 versus 46 percent) [16]. However, side effects caused by sertraline included nausea, vomiting, diarrhea, insomnia, and dry mouth.

● A five-week trial compared fluoxetine (20 mg/day) with placebo in patients with SAD (n = 66) and found that response (reduction of baseline symptoms ≥50 percent) occurred in more patients treated with fluoxetine than placebo (59 versus 34 percent) [46]. The most frequent side effects in patients receiving fluoxetine were headache and flu-like symptoms.

● A six-week randomized trial compared fluoxetine (20 to 40 mg/day) with moclobemide (300 to 450 mg/day) in patients with depressive disorders (n = 147); SAD was present in 29 of the patients with depressive disorders [47]. Response (reduction of baseline symptoms ≥50 percent) to either fluoxetine or moclobemide was comparable in patients with SAD and patients with nonseasonal depression (66 and 60 percent). Among patients with SAD, response to fluoxetine or moclobemide was comparable.

In addition, randomized trials that compared antidepressants with bright light therapy in patients with SAD found that efficacy was comparable. Although interpretation of the results in both studies was complicated by lack of a group receiving no active treatment, the findings nevertheless suggested that antidepressants can be effective for SAD:

● An eight-week trial compared fluoxetine (20 mg/day) plus sham light therapy (100 lux for 30 minutes each day) with placebo pill plus bright light therapy (10,000 lux for 30 minutes each day) in 96 patients with SAD [48]. Response (reduction of baseline
symptoms ≥50 percent) in the two groups was identical (67 percent of patients). Sleep disturbance, agitation, and palpitations occurred more often with fluoxetine than bright light.

● A five-week trial compared fluoxetine (20 mg/day) plus sham light therapy (100 lux for two hours each day) with placebo pill plus bright light therapy (3000 lux for two hours each day) in 40 patients with SAD [49]. Response (reduction of baseline symptoms ≥50 percent) to fluoxetine or bright light therapy was comparable (65 and 70 percent of patients).

Although other studies found that antidepressants were not helpful for SAD, the lack of benefit may have been due to methodologic problems:

● Three randomized trials [46,48,49] were included in a systematic review [50] that compared second-generation antidepressants (eg, SSRIs) with control conditions in patients with SAD; the review concluded that there was poor evidence for the efficacy of any second-generation antidepressant in treating SAD. However, the investigators excluded the sertraline trial discussed above because it included patients whose underlying condition was bipolar disorder (5 percent of the sample) [16]. Also, the systematic review emphasized that in one of the trials discussed above, which compared fluoxetine with placebo [46], the continuous outcome measure failed to show a statistically significant difference between the two groups; nevertheless, the categorical outcome measure of response did show a statistically significant difference.

● A three-week randomized trial compared moclobemide (400 mg per day) with placebo in patients with SAD (n = 34) [51]. Improvement of depressive symptoms in the two groups was comparable. However, the negative results may have been due to the trial’s short duration and small sample size, as well as the relatively low dose of moclobemide.

Bright light therapy — Several randomized trials indicate that artificial bright white light is efficacious for patients with SAD, and clinicians can expect that response or remission will occur in approximately 60 percent of patients [30,52,53]. As an example:

● A meta-analysis of eight trials (n = 360 patients with SAD) compared bright light therapy with control conditions and found a significant, large clinical effect favoring bright light [54]. In one of the biggest and longest (four weeks) trials, which compared bright light therapy (6000 lux; n = 33) with placebo (deactivated negative ion generator; n = 31), remission occurred in more patients who received light therapy than placebo (61 versus 32 percent) [53].
● A subsequent meta-analysis, using a different set of eight trials (n = 343 patients with SAD), found a significant, moderate clinical effect favoring bright light over control conditions [55]. One of the more recent trials (n = 37), lasting three weeks, compared bright light therapy (10,000 lux for 30 minutes) with low flow rate negative air ionization (2 x 1011 ions/second for 93 minutes) [30]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients treated with bright light therapy than low flow negative ions (12/19 versus 3/18 [63 versus 17 percent]).

Among patients with SAD, the factor that appears to be most consistently associated with a good response to bright light therapy is hypersomnia [29,56-58]. Other factors that may be associated with positive responses include hyperphagia (especially carbohydrate craving) and a less severe symptom profile at baseline [29,56,58-60].

Response to bright light therapy is not specific to SAD; bright light therapy can be efficacious for nonseasonal depressive syndromes [29,54,61-64]. However, three observational studies suggest that response to bright light therapy is greater in patients with SAD than nonseasonal depression [61]. The efficacy of bright light therapy for nonseasonal unipolar depression is discussed separately. (See "Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Bright light therapy'.)

In addition, augmentation with bright light therapy administered at midday (eg, between 12:00 PM and 2:30 PM) may be efficacious for treatment of nonseasonal bipolar depression. (See "Bipolar major depression in adults: Investigational and nonstandard approaches to treatment", section on 'Bright light therapy'.)

Time of day — Several randomized trials indicate that bright light therapy for SAD is more beneficial if it is administered early in the morning rather than later in the morning or in the evening [53,57,65]:

● A pooled analysis of patient level data from 29 studies (n = 332 patients) found that remission occurred in more patients who received light therapy in the morning, compared with therapy at midday or in the evening (53 versus 32 and 38 percent) [59]. In addition, exposure in both the morning and evening provided no additional benefit over morning exposure alone.

● A subsequent two-week trial compared morning bright light therapy (initiated 10 minutes after awakening) with evening bright light therapy (initiated two to three hours before bedtime) [31]. Patients (n = 85) received 10,000 lux for 30 minutes per day in each treatment session. Remission occurred in more patients who received light therapy in the morning than the evening (54 versus 33 percent).

● Another two-week trial compared morning bright light therapy (2500 lux, 6 to 8 AM each day) with evening bright light therapy (7 to 9 PM) in 51 patients [66]. Improvement was greater with morning light therapy than evening light therapy.

Dawn simulation — Several randomized trials have found that dawn simulation is beneficial for winter depression, and the benefit may be comparable to bright light therapy [67]. Clinicians can expect that response or remission will occur in approximately 65 percent of patients:


● A meta-analysis of five randomized trials compared dawn simulation with control conditions (eg, dim red light) in 133 patients with SAD [54]. Improvement was greater with dawn simulation and the benefit was clinically moderate to large. As an example, the largest trial (n = 62) found that remission occurred in more patients who received dawn simulation (90 minutes dawn signal, incandescent light peaking at 250 lux) than dim red light (90 minutes) (68 versus 48 percent) [68].

● In a subsequent three-week trial, 58 patients with winter depression were randomly assigned to dawn simulation, bright light therapy (10,000 lux for 30 minutes), or low flow rate negative air ionization (2 x 1011 ions/second) [30]. The dawn simulator initially delivered 0.0003 lux to patients as they slept; the intensity of light then progressively increased to 250 lux over 93 minutes. Response, defined as reduction of baseline symptoms ≥50 percent, occurred in more patients treated with dawn simulation or bright light therapy, compared with low flow rate ions (13/21 and 12/19 versus 3/18 patients [62 and 63 versus 17 percent]).

In addition, a pooled analysis of three randomized trials compared dawn simulation with dim light (placebo) in patients with SAD and hypersomnia (n = 50), and found that dawn simulation ameliorated difficulty awakening and morning drowsiness [69].

Psychotherapy — Many randomized trials in patients with nonseasonal major depression provide indirect evidence that for patients with SAD, adjunctive psychotherapy is beneficial. The evidence that psychotherapy plus pharmacotherapy is efficacious for the general treatment of unipolar major depression is discussed separately. (See "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Psychotherapy' and "Major depressive disorder in adults: Approach to initial management", section on 'Severe major depression'.)

In addition, there is direct evidence that psychotherapy is effective for patients with unipolar major depression with seasonal pattern (winter depression). Multiple randomized trials from the same research group have found that CBT, adapted for SAD, can be helpful; patients learn to challenge dysfunctional thoughts about winter and to change problematic behaviors (eg, social isolation). Clinicians can expect that remission will occur in approximately 50 percent of patients:

● A six-week trial compared CBT with bright light therapy in patients (n = 177) with winter SAD [14]. CBT was administered twice weekly in 90-minute group sessions; bright light therapy consisted of 10,000 lux light, typically used for 30 to 60 minutes per day. In addition, 25 percent of the patients continued antidepressant medications that had been started prior to the study. Remission was nearly identical in the two groups (approximately 47 percent of patients), and none of the patients discontinued treatment due to side effects. However, fewer patients appeared to accept CBT; discontinuation of CBT or light therapy occurred in 15 and 1 percent of patients.


After completion of the trial, patients were instructed to resume their study treatment (CBT skills or light therapy) during the next autumn and winter. Follow-up during the first year after treatment found that recurrence of depression in the next winter was comparable in patients who were treated with CBT or bright light therapy (29 and 25 percent) [70]. However, in the second year of follow-up (two winters after treatment), relapse occurred in fewer patients who had received CBT than light therapy (27 versus 46 percent); only 31 percent of the group initially treated with light therapy had resumed light therapy for the second winter.

The finding that CBT is effective for maintenance treatment of SAD is consistent with randomized trials in the general population of patients with unipolar major depression, which compared CBT with antidepressants; improvement posttreatment was comparable, but subsequent to discontinuation of treatments, there were fewer recurrences in patients who were acutely treated with CBT than antidepressants. (See "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Relapse/recurrence in the absence of treatment'.)

● A six-week trial randomly assigned patients (n = 61) to one of four treatments: group CBT (twice weekly sessions, 90 minutes/session), bright light therapy (10,000 lux for 90 minutes daily), group CBT plus light therapy, or a waiting list (control) [71]. Improvement was greater with each of the three active treatments compared with the waiting list, and remission occurred in more patients who received combination therapy than controls (11/15 versus 3/15 patients [73 versus 20 percent]).
Adjunctive interventions — Several adjunctive interventions are encouraged throughout acute and maintenance treatment, on the basis of the following evidence [11]:

● Sleep hygiene – Sleep hygiene ( table 6), including a regular sleep-wake cycle, was encouraged for all patients in many of the randomized trials that studied light therapy [31,53,57,66] (see 'Bright light therapy' above). As part of sleep hygiene, creating a regular light-dark cycle may be important. Winter depression is often characterized by phase-delayed circadian rhythms relative to sleep, which can cause initial insomnia. Excessive light during the two hours prior to the desired time of sleep onset may delay circadian rhythms and cause initial insomnia and difficulty awakening. Minimizing light exposure in the late evening, especially blue light from computer monitors and televisions, facilitates sleep onset and helps shift circadian rhythms counterclockwise [72]. Circadian rhythms and SAD are discussed separately. (See "Seasonal affective disorder: Epidemiology, clinical features, assessment, and diagnosis", section on 'Pathogenesis'.)


● Daily walks outside – A prospective observational study of patients with SAD compared the benefits of natural light obtained by daily walks outside each morning for 60 minutes (n = 20 patients) with the benefits of artificial light therapy administered each day with a 2800 lux light box for 30 minutes per day (n = 8 patients) [73]. The study was conducted during winter and lasted three weeks. Improvement was greater in patients who walked outside. However, 2800 lux is generally regarded as an insufficient dose for bright light therapy (see 'Administration' below). In addition, walking outside may include elements of the psychotherapy called behavioral activation.


Daily walks outside may be beneficial even on cloudy days. The light intensity of different environments is approximately as follows [3,12]:



• Bright midday sun – 50,000 to 100,000 lux

• Cloudy day – 1000 to 5000 lux

• Indoor office lighting – 500 lux

• Indoor home lighting – 250 lux

By comparison, standard light boxes for administering bright light therapy emit 10,000 lux. (See 'Administration' below.)
● Aerobic exercise – Open-label, randomized trials suggest that aerobic exercise may help with SAD:

• A randomized trial compared exercise (stationary bicycle for one hour each day) with no treatment in patients with winter depression (n = 18) and found that improvement was greater in the group that exercised [74].

• An eight-week trial during late fall and early winter compared aerobic exercise conducted in normal light (400 to 600 lux) with relaxation training conducted in dim light [75]. Aerobic exercise occurred two to three times per week, with each session lasting one hour; relaxation training occurred once per week for one hour. The study subjects were relatively healthy, but measurable depressive symptoms were present and subsyndromal SAD was identified in roughly 40 percent of the subjects. Analyses of the subjects (n = 51) who completed the trial found that improvement was greater with aerobic exercise than relaxation training.

• A subsequent eight-week trial during late fall and early winter compared aerobic exercise conducted in bright light (2500 to 4000 lux) with stretching and relaxation training conducted in bright light [76]. Both interventions occurred twice per week and lasted 45 minutes. Although the study subjects were relatively healthy, many patients manifested measurable depressive symptoms and subsyndromal SAD was present in approximately 40 percent. Analyses of the subjects (n = 69) who completed the trial showed that improvement of depressive symptoms was greater with aerobic exercise than stretching/relaxation.

Maintenance treatment — By definition, winter seasonal depression is a recurrent illness. Maintenance treatment is typically indicated to prevent recurrences, especially among patients who suffer suicidal ideation and behavior, or impairment that threatens occupational or interpersonal functioning [11]. (See "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Indications'.)


The same treatment that was successfully used acutely is typically selected for maintenance treatment (eg, antidepressants and/or light therapy). Although it is theoretically possible to use sequential treatment, in which acutely ill patients are successfully treated with one therapy (eg, bright light therapy), and then administered a different treatment (eg, pharmacotherapy) [77,78], we never use this approach.

In addition, we encourage patients to incorporate all of the following adjunctive interventions throughout their entire course of maintenance (and acute) treatment:
● Sleep hygiene ( table 6)

● Daily walks outside, even on cloudy days

● Aerobic exercise

● Enhanced indoor lighting with regular lamps and fixtures

● Dawn simulation (see 'Dawn simulation' below)

Evidence for the efficacy of adjunctive treatments for winter depression is discussed elsewhere in this topic. (See 'Efficacy of acute treatment' above.)

Antidepressants — Following response to acute treatment with antidepressant medications, either as monotherapy or in conjunction with light therapy, antidepressants are continued for at least two weeks beyond the usual spontaneous offset of winter depression [11]. Based upon randomized trials in patients with nonseasonal unipolar major depression, premature discontinuation of pharmacotherapy can precipitate relapse. (See "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Compared with placebo'.)


Maintenance treatment for winter depression that responds to antidepressants includes the following two approaches [20]:

● Seasonal pharmacotherapy – The antidepressant is tapered and discontinued in the spring or summer, and resumed in the fall at least four weeks prior to the expected onset of symptoms (based upon prior history). Evidence supporting the use of seasonal pharmacotherapy includes three randomized trials that compared bupropion (150 or 300 mg per day) with placebo in patients (total n = 1042) with a history of winter depression [4,79]. Patients were enrolled during autumn while still euthymic and treated until spring. Relapse during treatment occurred in fewer patients treated with bupropion than placebo (15 versus 27 percent). However, discontinuation of treatment due to adverse effects was nearly two times greater with bupropion than placebo (9 and 5 percent of patients). Side effects that occurred more often with bupropion than placebo included headache, insomnia, and nausea [79].


Following the end of treatment, recurrences of depression in spring and summer were comparably low for the groups that were treated with bupropion or placebo (3 and 2 percent) [4].
For patients with winter depression who discontinue their antidepressant in the spring/summer and then resume it in the fall, education about the symptoms of major depression and SAD may help patients detect prodromal signs of recurrence and begin treatment prior to onset of a full-blown major depressive episode [80]. The symptoms of major depression ( table 1) and SAD are discussed separately. (See "Depression in adults: Clinical features and diagnosis", section on 'Clinical features' and "Seasonal affective disorder: Epidemiology, clinical features, assessment, and diagnosis", section on 'Symptoms'.)

● Continuous pharmacotherapy – Antidepressants are maintained all year long. Evidence supporting the use of continuous treatment includes randomized trials conducted in the general population of patients with unipolar major depression. (See "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Antidepressant medications'.)

The choice between seasonal pharmacotherapy and continuous pharmacotherapy depends upon past history and patient preferences. As an example, some patients will opt to discontinue their antidepressant to avoid the side effects, inconvenience, and cost of daily medication. By contrast, patients may want to maintain the drug all year if there is a prior history of having discontinued the drug during the spring and summer and relapsing shortly thereafter. Year-round maintenance pharmacotherapy is also indicated for patients with severe winter depressive episodes. (See 'Severity of winter depression' above.)

Euthymic patients who are not currently treated with antidepressants may present to clinicians and report a history consistent with winter depression. For these patients, antidepressants can be started either immediately or in the fall, in an attempt to prevent recurrence of winter depression.

Light therapy — Following response to acute treatment with light therapy, either as monotherapy or in conjunction with pharmacotherapy, light therapy is continued for at least two weeks beyond the usual spontaneous offset of winter depression; premature discontinuation of light therapy (bright light therapy or dawn simulation) can precipitate relapse [12,43]. The usual offset of winter depression occurs when sufficient daily light exposure is available to patients through other sources, such as spring or summer sunlight. Light therapy is discontinued abruptly, without tapering [29].

For patients who respond to bright light therapy and continue treatment until the usual spontaneous offset of winter depression, it is reasonable to experiment with shorter daily exposures [7,11]. As an example, patients may decrease exposure from 30 to 25 or 20 minutes per day. However, if patients begin to decompensate, they should resume the duration that was initially effective.
Patients with winter depression who respond to light therapy typically discontinue treatment for the summer. However, if patients become depressed during a period of rainy or cloudy weather, light therapy should be resumed and then discontinued following remission [29].


For patients who discontinued light therapy in the spring or summer, we suggest resuming treatment in the fall, two to four weeks before the usual onset of winter depression [20,29]. Light treatment can be restarted earlier if prodromal winter depression symptoms occur earlier than usual.

Low quality evidence supports using light therapy as prophylaxis for winter depression:

● One randomized trial (n = 12 patients with SAD) compared bright light therapy started in late summer while patients were euthymic, with bright light therapy initiated after onset of prodromal depressive symptoms [81]. Light therapy in both groups was administered at a dose of 3300 lux for one hour each day, until early spring. Depressive symptom rating scale scores during fall and winter showed a significant, clinically large effect favoring the group that started light therapy while euthymic. Methodologic problems with this study include the small number of patients. In addition, the study evaluated the same intervention in two types of patients (one group euthymic and the other group with prodromal symptoms); a conventional randomized trial assigns the same type of patients to different types of interventions [82].


● Another randomized trial compared bright light therapy with no light therapy in patients with SAD who completed the study (n =

23) [83]. Patients were enrolled during the fall while still euthymic; bright light therapy consisted of 2500 lux administered 30 minutes per weekday with a visor. Recurrence of depression during treatment occurred in fewer patients who received bright light therapy than controls (36 versus 78 percent). Methodologic problems with this study include the small number of patients; in addition, the study used a per protocol (completer) analysis, rather than an intent to treat analysis [82].

Bright light therapy — The parameters that are used to describe light therapy include intensity (lux), wavelength, time of day for exposure, and duration of daily exposure [12]. The effect of bright light therapy is probably mediated through the eyes rather than the skin [84].


Administration — Bright light therapy is administered on a daily basis according to the following protocol [11-14,19,29,53,80,84-87]:
● Device – The standard and best studied devices for administering bright light therapy are 10,000 lux light boxes that use fluorescent bulbs emitting white light. (Incandescent light poses risks to the cornea and retina.) Although light boxes emitting less than 10,000 lux can be used, longer exposures are required. Commercially available fixtures are recommended over homemade devices, due to difficulty in measuring light intensity, and to reduce electrical hazards and other risks (eg, corneal and eyelid burns) associated with poor-quality construction. In addition, patients are advised to seek light boxes designed to protect the eyes with features such as light dispersion and screens that filter out ultraviolet rays. Ultraviolet light is not necessary for the therapeutic effect of bright light therapy and should be avoided to reduce potential risks to the skin or eyes.

● Positioning and distance – The light box should be positioned at a distance that enables patients to receive 10,000 lux while seated and facing the box, with the light projected downward to minimize aversive glare. Commercial light box instructions should give the distance at which 10,000 lux is achieved, which is typically approximately 40 to 80 cm (16 to 31 inches). The distance from the eyes to the light box is important because light intensity follows the inverse square law; if the distance between the eye and the light source is doubled, the intensity of light that is received drops to one-quarter of the original intensity.

● Time of day – Bright light therapy generally commences in the early morning, soon after awakening (eg, 7:00 AM). Patients should administer light therapy at approximately the same time each day, including weekends, holidays, and vacations. Most light therapy studies required a regular time for light treatment to start and thus stipulated a regular wake-up time for the subjects. A regular wake-up time may be important for optimal effectiveness of the bright light treatment. The effectiveness of variable timing of the bright light therapy is unknown.

If morning bright light treatment alone is not fully effective after two to four weeks of treatment, adding evening (eg, 8:00 PM) bright light treatment may be helpful. A minority of patients with SAD may benefit from bright light in the evening rather than morning bright light [80]. The self-report version of the Morningness-Eveningness Questionnaire is in the public domain and can be used to determine the best time of day to commence bright light therapy. However, the questionnaire is generally used for research rather than standard clinical care.


● Duration of exposure – The duration of early morning exposure to standard light boxes emitting 10,000 lux is generally 30 minutes/day, but some studies have used 45 or 60 minutes per session. However, no head-to-head trials have compared the efficacy of different lengths of exposure.
For patients who do not respond to initial treatment with 30 minutes/day, some studies have increased the duration of exposure to 45 minutes/day, and if nonresponse persists, to 60 minutes/day ( algorithm 1). However, no studies have compared the efficacy of a fixed dose of 30 minutes/day with an increasing dose, and the potential benefit of increasing exposure must be weighed against the added time burden.

If evening bright light therapy is added, the duration of evening exposure is generally 30 to 60 minutes. Patients who switch from morning to evening exposure continue the same length of exposure.

Bright light boxes emitting light that is less than 10,000 lux require longer exposures. As an example, morning light therapy with a 2500 lux light box requires an exposure of two hours to achieve the same benefit of 10,000 lux for 30 minutes.

● Looking at the device – The eyes are open during bright light therapy, with light visible at least in the peripheral vision. Patients can glance at the box but should avoid staring directly at the light.

● Patient activity – During bright light therapy, patients can engage in any activity, such as reading, eating, watching television, or working on a computer. Although patients are typically seated, it is reasonable to place the light box on a stand so that patients can engage in other activities, such as riding a stationary bicycle.

Safety — Light therapy is generally safe [17-19,61], and there are no absolute medical contraindications [19]. If light therapy is indicated and there is concern about the safety of the bright light therapy, dawn simulation (increasing to 250 lux) is a reasonable alternative. (See 'Dawn simulation' below.)

Although retinal damage is a theoretical adverse effect of bright light therapy based upon some rodent studies [88], there is little to no evidence that bright light therapy causes retinal damage in humans [19,89]. Given that the light intensity of bright light therapy (eg, 10,000 lux) is much less than the intensity of bright midday sun (eg, 50,000 to 100,000 lux) [3,12], the potential for retinal toxicity is minimal [29]. In a prospective study of patients (n = 17) with winter depression, whose eyes were examined and tested at baseline and then periodically during bright light therapy in the fall and winter months for three to six years, no ocular abnormalities were observed [90].
Nevertheless, for patients undergoing bright light therapy, we recommend consultation with an ophthalmologist at baseline and annually thereafter in the following situations [12,19,29,80,91,92]:

● Preexisting ophthalmological conditions (eg, cataract, glaucoma, macular degeneration, retinal detachment, or retinitis pigmentosa)

● Systemic diseases (eg, diabetes) that can involve the retina or render the eyes vulnerable to phototoxicity

● Family history of ophthalmological disease

● Use of photosensitizing drugs (eg, hydrochlorothiazide, lithium, tetracycline, or tricyclic antidepressants)

In addition, caution using bright light therapy is warranted for patients who have photosensitive skin [12,19,91,92]. Light induced migraine headaches or epilepsy are generally not contraindications to bright light therapy.

Side effects — Properly administered bright light therapy is generally well tolerated, and few patients discontinue treatment because of adverse effects [17-19,21,29,80]. Reported side effects, which are typically mild and reversible, include [13,19,80,89,93]:

● Agitation

● Anxiety

● Eye strain, photophobia, or visual disturbance

● Fatigue

● Headache

● Insomnia (if therapy is administered too late or too early in the day)

● Irritability

● Nausea

The most frequent problems appear to be eye strain and headache.

Before commencing bright light therapy, clinicians should assess patients for each of the symptoms that may emerge as side effects. In many cases, the symptoms are present at baseline and resolve after light treatment [29,89].
Side effects of bright light therapy may resolve with watchful waiting, and are likely to respond to a "dose" reduction that can be accomplished by decreasing the duration of sessions, increasing the distance from the light source, or taking periodic breaks (eg, for five minutes) during sessions.

Patients with bipolar major depression with seasonal features should be warned that bright light therapy may possibly induce hypomania or mania. (See 'Bipolar disorder with seasonal pattern' below.)

Dawn simulation — Dawn simulation is a form of light therapy that is administered during the final hours of sleep, but uses less intense white light than bright light therapy. Exposure begins in the early morning before patients awaken, using a device that emits a low level of light that gradually increases to room light level (approximately 250 lux) over a period of 30 to 90 minutes. Termination of exposure is timed to coincide with the patient’s habitual wakeup time.

Some patients prefer dawn simulation over bright light therapy, which requires making time to sit in front of the bright light. In addition, dawn simulation and bright light therapy are not mutually exclusive and we often use them concomitantly; together they can provide a light environment in the winter that more closely resembles a summer morning.


SUMMER DEPRESSION

Summer depression is characterized by recurrent episodes of unipolar major depression that begin in the spring to summer, and if left untreated, generally remit during the following fall or winter. (See 'Seasonal pattern' above.)

Summer depression is managed with standard treatments that are used for the general population of patients with unipolar major depression. (See "Major depressive disorder in adults: Approach to initial management" and "Unipolar depression in adults: Choosing treatment for resistant depression".)

In addition, clinical experience suggests that patients with summer depression may perhaps benefit from two adjunctive interventions:

● Limit exposure to natural daylight (eg, no more than 13 hours per day)

● Stay cool with air conditioning, especially at night

BIPOLAR DISORDER WITH SEASONAL PATTERN

Bipolar mood episodes with seasonal pattern are treated in the same manner as nonseasonal episodes. (See "Bipolar major depression in adults: Choosing treatment" and "Bipolar mania and hypomania in adults: Choosing pharmacotherapy" and "Bipolar disorder in adults: Choosing maintenance treatment".)

For patients with bipolar major depression with seasonal pattern who do not respond to standard treatments, it is reasonable to attempt a trial of adjunctive bright light therapy. A regimen of standard antimanic pharmacotherapy, such as lithium, valproate, second-generation antipsychotics, or carbamazepine, should be established (eg, for one month) prior to using light therapy [80,86].

In addition, patients should be warned that bright light therapy may possibly induce hypomania or mania. However, this appears to be rare [19,89]. If there are concerns about switching from depression to hypomania or mania (eg, there is a prior history of switching when treated with antidepressant drugs), bright light therapy can be started at a low dose and titrated up gradually. As an example, on day 1 clinicians can prescribe five minutes of bright light and then increase exposure by five-minute increments each day until 30 minutes/day is reached on day 6. Clinicians should also monitor patients for emerging hypomanic/manic symptoms. For example, outpatients can be seen weekly for the first two weeks, with the subsequent frequency determined by response and side effects. If morning bright light treatment is associated with new onset insomnia, the bright light treatment is stopped until the insomnia resolves and is then restarted at a lower intensity or shorter duration.


Following response to acute treatment with adjunctive light therapy in conjunction with pharmacotherapy, light therapy is continued for at least two weeks beyond the usual spontaneous offset of winter depression; premature discontinuation of light therapy can precipitate relapse. Pharmacotherapy is continued indefinitely. (See 'Light therapy' above and "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Maintenance of medications'.)

The administration, safety, and side effects of bright light therapy are discussed elsewhere in this topic. (See 'Bright light therapy' above.)

Low quality evidence supporting the use of add-on light therapy for bipolar major depression with seasonal pattern includes the following [20]:
● A six-week trial enrolled patients with bipolar I or II major depression who had not responded to pharmacotherapy, and randomly assigned them to adjunctive bright light therapy (7000 lux) or placebo (dim red light, 50 lux). Patients were not selected on the basis of a diagnosis of major depression with seasonal features and were enrolled throughout all four seasons. Nevertheless, seasonality traits were present in more than 80 percent of patients, and nearly 75 percent were enrolled during the fall and winter. Add-on study treatments were administered at midday (between 12:00 PM and 2:30 PM) and the target dose was 60 minutes per day by week 4 [94]. Among patients who completed at least one study visit between weeks 4 and 6 (n = 40), remission was greater with bright light therapy than dim red light (68 versus 22 percent). In addition, functioning improved more with bright light therapy. None of the study patients switched polarity. However, the study results may have been biased, because the analyses included only the patients who completed at least one study visit between weeks four and six (n = 40), rather than all of the patients who were initially randomized (n = 46).


The choice of midday bright light may have been important. In prior, small prospective observational studies, bright light in the morning was associated with mood instability and worsening, whereas midday light appeared to be beneficial [95,96].

● A two-week trial enrolled patients with bipolar major depression who had not responded to pharmacotherapy and randomly assigned them to adjunctive bright light therapy (5000 lux) or placebo (dim red light, <100 lux) [97]. Patients with seasonal affective disorder were not specifically included, and seasonality traits were not assessed; both inpatients and outpatients were included. Add-on study treatments were administered in the morning for 60 minutes. Among the patients who completed the study (n = 63), response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received bright light therapy than placebo (79 versus 43 percent). One patient in each group became more irritable, but otherwise no manic symptoms emerged, and the treatment was well tolerated. However, the study results may have been biased because the analyses included only the patients who completed the study (n = 63), rather than all of the patients who were initially randomized (n = 74).

● A two-week study enrolled patients with bipolar major depression (n = 32) who had not responded to medications and assigned them to adjunctive bright light therapy (10,000 lux) or a dim light (<500 lux) control condition [98]. The study states that patients were randomized according to the order in which they were admitted to the study, which may mean that patients were alternately assigned to bright light therapy and dim light, rather than randomly. In addition, only patients were blind to treatment assignment, and only 7 (22 percent) patients had a seasonal pattern. Remission occurred in more patients who received bright light therapy
than dim light (7/16 versus 2/16 [44 versus 13 percent]). Among the 16 patients assigned to bright light therapy, four had a seasonal pattern, and remission with bright light therapy was more likely to occur in patients who had a seasonal pattern than those who did not (4/4 versus 3/12 [100 versus 25 percent]).



SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Depressive disorders".)



INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

● Basics topics (see "Patient education: Seasonal affective disorder (The Basics)")

Additional information for patients about seasonal affective disorder is provided by the Society for Light Therapy and Biological Rhythms and Center for Environmental Therapeutics.




SUMMARY AND RECOMMENDATIONS
● Definition and general treatment principles – Seasonal affective disorder (SAD) is defined as recurrent episodes of major depression, mania, or hypomania with seasonal onset and remission. It is not considered a separate mood disorder; rather, SAD is a subtype of unipolar major depressive disorder, bipolar I disorder, and bipolar II disorder. The treatment of SAD depends upon the specific mood disorder that is present and the severity of illness. This topic focuses primarily upon recurrent unipolar major depression with winter seasonal pattern (winter depression). (See 'Definitions' above and 'General principles' above.)

● Acute treatment – The primary treatments for SAD include antidepressants, light therapy, and psychotherapy. Adjunctive interventions include sleep hygiene ( table 6), daily walks outside, aerobic exercise, enhanced indoor lighting, and awakening from sleep with light. (See 'Approach to acute treatment' above.)

• First line – For patients with winter depression, we suggest an antidepressant drug plus artificial light (bright light therapy, dawn simulation, or both) as first line treatment, rather than other treatment regimens (Grade 2C). However, antidepressants alone are a reasonable alternative. The initial drug of choice is typically a selective serotonin reuptake inhibitor. For patients with mild to moderate winter depression, light therapy alone is also a reasonable alternative as first line therapy. However, light therapy alone is generally regarded as inadequate for severe episodes of winter depression. (See 'First line' above and 'Severity of winter depression' above.)


• Second line – For patients who do not respond satisfactorily to first line treatment with an antidepressant drug plus light therapy, we suggest switching antidepressants and continuing light therapy as second line treatment, rather than other treatment regimens (Grade 2C). (See 'Second line' above.)

For patients with winter depression who partially respond to first line treatment with antidepressants alone, we continue the drug and add artificial light (bright light therapy, dawn simulation, or both) as second line treatment. For patients who respond minimally or not all to first line treatment with antidepressants alone, we switch the drug and add light therapy. (See 'Second line' above.)


For patients with winter depression who do not respond to first line treatment with light therapy alone, we continue light therapy and add an antidepressant drug as second line treatment. (See 'Second line' above.)
• Third line – Winter depression that does not respond to first- and second-line therapies is generally managed by adding psychotherapy as third line treatment. We typically use cognitive-behavioral therapy; however, other psychotherapies (eg, interpersonal psychotherapy) are reasonable alternatives. (See 'Third line' above.)

• Other options – Patients with severe winter depression who do not respond to first, second-, and third-line therapies may be candidates for electroconvulsive therapy. (See 'Other options' above.)

● Maintenance treatment – By definition, winter depression is a recurrent illness, and maintenance treatment is typically indicated to prevent recurrences, especially among patients who suffer suicidal ideation and behavior, or impairment that threatens occupational or interpersonal functioning. The same treatment that was successfully used acutely is typically selected for maintenance treatment. (See 'Maintenance treatment' above and "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Indications'.)





ACKNOWLEDGMENT

The UpToDate editorial staff acknowledges Sy Atezaz Saeed, MD and Timothy J Bruce, PhD who contributed to an earlier version of this topic review.


DSM-5-TR diagnostic criteria for a major depressive episode


A. Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.

NOTE: Do not include symptoms that are clearly attributable to another medical condition.


1) Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad, empty, hopeless) or observations made by others (eg, appears tearful). (NOTE: In children and adolescents, can be irritable mood.)

2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).

3) Significant weight loss when not dieting or weight gain (eg, a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (NOTE: In children, consider failure to make expected weight gain.)


4) Insomnia or hypersomnia nearly every day.


5) Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).


6) Fatigue or loss of energy nearly every day.


7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).

8) Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by their subjective account or as observed by others).


9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.


B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.


C. The episode is not attributable to the direct physiological effects of a substance or to another medical condition.


NOTE: Criteria A through C represent a major depressive episode.


NOTE: Responses to a significant loss (eg, bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a

depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgement based on the individual's history and the cultural norms for the expression of distress in the context of loss.


D. The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.


E. There has never been a manic or hypomanic episode.


NOTE: This exclusion does not apply if all of the manic-like or hypomanic-like episodes are substance-induced or are attributable to the physiological effects of another medical condition.


Specify:


With anxious distress


With mixed features


With melancholic features


With atypical features


With psychotic features


With catatonia


With peripartum onset


With seasonal pattern

Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note:

These diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.



Graphic 89994 Version 16.0
DSM-5-TR diagnostic criteria for bipolar major depression



A. Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.

NOTE: Do not include symptoms that are clearly attributable to another medical condition.

1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad, empty, hopeless) or observations made by others (eg, appears tearful). (NOTE: In children and adolescents can be irritable mood.)
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).
3. Significant weight loss when not dieting or weight gain (eg, a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (NOTE: In children, consider failure to make expected weight gain.)

4. Insomnia or hypersomnia nearly every day.

5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).

6. Fatigue or loss of energy nearly every day.

7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by their subjective account or as observed by others).

9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.


B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.


C. The episode is not attributable to the direct physiological effects of a substance or to another medical condition.


NOTE: Criteria A through C represent a major depressive episode.


NOTE: Responses to a significant loss (eg, bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgement based on the individual's history and the cultural norms for the expression of distress in the context of loss.
D. The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.


Specify:

With anxious distress

With mixed features

With rapid cycling

With melancholic features

With atypical features

With psychotic features

With catatonia

With peripartum onset

With seasonal pattern


Adapted from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note: The original diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.


Graphic 91398 Version 10.0
DSM-5-TR diagnostic criteria for manic episode



A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least one week and present most of the day, nearly every day (or any duration if hospitalization is necessary).

B. During the period of mood disturbance and increased energy or activity, three (or more) of the following symptoms (four if the mood is only irritable) are present to a significant degree and represent a noticeable change from usual behavior:
1. Inflated self-esteem or grandiosity.

2. Decreased need for sleep (eg, feels rested after only three hours of sleep).

3. More talkative than usual or pressure to keep talking.

4. Flight of ideas or subjective experience that thoughts are racing.

5. Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli), as reported or observed.

6. Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation (ie, purposeless non-goal-directed activity).
7. Excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments).

C. The mood disturbance is sufficiently severe to cause marked impairment in social or occupational functioning or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features.

D. The episode is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication, other treatment) or to another medical condition.

NOTE: A full manic episode that emerges during antidepressant treatment (eg, medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a manic episode and, therefore, a bipolar I diagnosis.


NOTE: Criteria A through D constitute a manic episode. At least one lifetime manic episode is required for the diagnosis of bipolar I disorder.



Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note:

These diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022.


Graphic 91106 Version 8.0
DSM-5-TR diagnostic criteria for hypomanic episode



A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least four consecutive days and present most of the day, nearly every day.

B. During the period of mood disturbance and increased energy and activity, three (or more) of the following symptoms (four if the mood is only irritable) have persisted, represent a noticeable change from usual behavior, and have been present to a significant degree:
1. Inflated self-esteem or grandiosity.

2. Decreased need for sleep (eg, feels rested after only three hours of sleep).

3. More talkative than usual or pressure to keep talking.

4. Flight of ideas or subjective experience that thoughts are racing.

5. Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli), as reported or observed.

6. Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation.

7. Excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments).


C. The episode is associated with an unequivocal change in functioning that is uncharacteristic of the individual when not symptomatic.


D. The disturbance in mood and the change in functioning are observable by others.


E. The episode is not severe enough to cause marked impairment in social or occupational functioning or to necessitate hospitalization. If there are psychotic features, the episode is, by definition, manic.

F. The episode is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication, or other treatment).

NOTE: A full hypomanic episode that emerges during antidepressant treatment (eg, medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a hypomanic episode diagnosis. However, caution is indicated so that one or two symptoms (particularly increased irritability, edginess, or agitation following antidepressant use) are not taken as sufficient for a diagnosis of a hypomanic episode, nor necessarily indicative of a bipolar diathesis.


NOTE: Criteria A through F constitute a hypomanic episode. Hypomanic episodes are common in bipolar I disorder but are not required for the diagnosis of bipolar I disorder.
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved. Note:

These diagnostic criteria remain unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association 2022

__________________________________
http://www.divisenko.ru/ (врач психотерапевт в Москве)


Вернуться к началу
 Профиль  
 
Показать сообщения за:  Поле сортировки  
Начать новую тему Ответить на тему  [ Сообщений: 92 ]  На страницу Пред.  1, 2

Часовой пояс: UTC + 3 часа


Кто сейчас на конференции

Сейчас этот форум просматривают: Bing [Bot] и гости: 381


Вы не можете начинать темы
Вы не можете отвечать на сообщения
Вы не можете редактировать свои сообщения
Вы не можете удалять свои сообщения
Вы не можете добавлять вложения

Найти:
Перейти:  

Создано на основе phpBB® Forum Software © phpBB Group
Русская поддержка phpBB
Яндекс.Метрика Яндекс.Метрика